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Haematopoietic stem cells (HSC) are responsible for the maintenance of blood 
homeostasis and are of fundamental importance for the treatment of a variety of life-
threatening diseases. However, their scarce availability constitutes a major obstacle. Thus, 
understanding their embryonic specification is essential for the production of these cells in vitro 
from human pluripotent stem cells (hPSC), but also to develop new therapies. During 
development, HSCs first arise in the aorta-gonad-mesonephros (AGM) region of the embryo 
from a population of haemogenic endothelial cells lining the ventral portion of the dorsal aorta 
which undergo endothelial-to-haematopoietic transition (EHT). This process culminates with 
the generation of the first HSCs capable of multilineage differentiation and long-term 
engraftment. Little is known about the molecular mechanisms driving this process, especially 
in human where the AGM region is not easily accessible in vivo.  
In this study, I took advantage of hPSCs and single cell transcriptomics to draw an 
accurate picture of this developmental stage and uncover mechanisms by which the haemogenic 
endothelium generates early HSCs. Of particular interest, I show that most of the endothelial 
cells at this stage reside in a quiescent state, with a direct correlation between cell cycle entry 
and their ability to progress to the haematopoietic fate. Furthermore, I identify CDK4/6 and 
CDK1 as key regulators affecting this process.  
Ultimately, I propose here a direct link between the molecular machineries controlling 
cell cycle progression and cell fate decision, determining the capability of haemogenic 
endothelial cells to undertake the haematopoietic fate during EHT.  
These results will have a major impact on the improvement of protocols for the 
production of functional HSCs in vitro, but also on the advancement of new therapies based on 
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The word haematopoiesis comes from the ancient Greek αἷμα, for “blood”, and ποιεῖν, 
which means “to make”. It describes the process by which, in a healthy adult person, 
approximately 1011-1012 new blood cells are produced daily (Parslow et al., 2001). This high 
demand of cells is essential for the maintenance of steady-state levels of circulating blood cells 
and is satisfied by haematopoietic stem cells, a population of adult stem cells residing in the 
medulla of the bone marrow and characterised by high regenerative capacity.  
Prompted by the incredible potential of this population for regenerative medicine, much 
effort has been spent on trying to achieve their derivation in vitro for clinical applications. For 
this, the main approach has involved the use of human pluripotent stem cells and manipulation 
of molecular signals in an attempt to recapitulate in a dish the developmental steps leading to 
the generation of the first haematopoietic stem cell. Signalling pathways controlling embryonic 
pluripotency and early differentiation, along with molecular mechanisms driving 
haematopoietic ontogeny and control of their self-renewal capacity, have been extensively 
studied, and have allowed considerable progress in the generation of blood products in vitro.  
In this respect, a special role is fulfilled by the cell cycle. This involves a complex network 
integrating signalling pathways and molecular mechanisms directing proliferation and cell fate 
decision, along with many other functions, and over the years has emerged as a key player 
controlling homeostasis and differentiation of haematopoietic stem cells, both during 





1.2 Haematopoietic stem cells 
 
Haematopoietic stem cells (HSCs) are a population of self-renewing multipotent cells that 
in adult mammals reside in the bone marrow. They are functionally defined by their ability to 
engraft upon transplant into an immunocompetent recipient and to reconstitute the whole 
haematopoietic system thanks to their capacity to differentiate and produce all the blood cells 
in the adult body.  This fundamental ability is the basis for procedures involving the use of bone 
marrow, peripheral blood or cord blood for the transplantation of HSCs into patients with life-
threatening diseases, a curative treatment for a number of malignant and non-malignant 
diseases of the haematopoietic system and for some solid tumours, a procedure whose use over 
recent years has continued to increase both in Europe and in the United States of America 
(BSBMT, 2013; NHS England, 2015; Passweg et al., 2017; D’Souza et al., 2017).  
HSCs are generally considered to be responsible for the production and replenishment of 
all the blood cells found in the adult body, despite recent evidence suggesting  that at least part 
of the tissue-resident macrophages might instead derive directly from embryonic progenitors 
and possess self-renewal capacity, therefore being HSC-independent (Ginhoux and Guilliams, 
2016; Hoeffel, 2018). Nevertheless, HSCs retain the fundamental role of sustaining lifelong 
maintenance of the whole haematopoietic system, thanks to their ability to differentiate and 
replenish mature blood cells which are predominantly short-lived.   
This differentiation towards mature blood lineages has been classically described as a 
process following a strict hierarchical tree-like structure, starting from HSCs at its top and 
transitioning through well-defined intermediate progenitors belonging to distinct routes of 
differentiation, characterised by progressive restriction in their fate potential (Figure 1.1A). 
This view was supported by the implementation of flow cytometry gating strategies allowing 
for the isolation of distinct populations which were defined by specific sets of surface markers 
(Venditti et al., 1999; Holyoake et al., 2000; Hao et al., 2001). According to this model, the first 
branch point was separating the lymphoid route from the erythro-myeloid potential, and was 
followed by subsequent ramifications of the hierarchy leading to fully committed blood cells. 
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Figure 1.1 Classical representation of haematopoiesis. (A) The haematopoietic hierarchy has been 
classically represented as a strict tree-like structure, with well-defined and separated intermediate stages 
gradually committing towards differentiated blood cells. (B) Progressively, this view has been integrated with 
new findings suggesting functional heterogeneity in the HSC pool and the existence of crosstalks between 
branches of differentiation previously thought to be separate (LT: long-term; ST: short-term; HSC: 
haematopoietic stem cells; MPP: multipotent progenitors; CLP: common lymphoid progenitors; CMP: common 
myeloid progenitors; GMP: granulocyte-monocyte progenitors; MEP: megakaryocyte-erythrocyte progenitors; 
LMPP: lymphoid-primed multipotential progenitors). 
 
However, it became clear over time that the reality was more complicated than previously 
thought. Indeed, a growing number of studies uncovered concepts that challenged the classical 
model: a crosstalk between different branches, and lymphoid progenitors contributing to the 
myeloid compartment (Adolfsson et al., 2005; Doulatov et al., 2010); the existence of direct 
routes of differentiation deriving megakaryocytes directly from HSCs (Sanjuan-Pla et al., 2013); 
and importantly, the identification of subpopulations of multipotent progenitors able of long-
term engraftment but possessing distinct fate propensities (Yamamoto et al., 2013; Pietras et al., 
2015; Carrelha et al., 2018). Particularly, the existence of lineage-biased stem cells led to the 
concept of HSC pool, comprising subpopulations with self-renewal ability but heterogeneous 
for their differentiation propensity. Furthermore, HSC ability to engraft upon transplant 
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appeared to be lost progressively, therefore also leading to the distinction between cells able to 
generate long-term (LT-HSCs) or short-term (ST-HSCs) engraftment (Figure 1.1B). 
The advent over recent years of microfluidics technologies have made possible the use of 
high-throughput single cell gene expression analyses for hundreds of cells, and more recently 
the transcriptome-wide RNA sequencing for the analysis of even thousands of individual cells, 
further unveiling the complexity of the haematopoietic tree (Warren et al., 2006; Guo et al., 
2013; Nestorowa et al., 2016; Velten et al., 2017). Following these breakthroughs, the 
haematopoietic stem/progenitor cell (HSPC) compartment appears today to be highly 
heterogeneous at the transcriptional level, populated of low-primed undifferentiated cells which 
progressively transition to oligopotent, bipotent or even directly to unipotent progenitor states. 
This transcriptional heterogeneity is in agreement with the previously mentioned single cell 
transplantation studies, highlighting the existence of lineage-biased HSCs characterised by 
distinct differentiation propensities (Sanjuan-Pla et al., 2013; Yamamoto et al., 2013; Carrelha 
et al., 2018). Additionally, this situation appears to be further complicated by similar functional 
studies performed on cells derived from distinct human developmental stages, showing that fate 
propensity of cells in the HSPC compartment, and the differentiation routes they follow, 
actually change during development, from foetal liver (FL-) to bone marrow (BM-) HSCs 
(Notta et al., 2015).  
Overall, these studies demonstrate that the haematopoietic hierarchy is not composed of 
clearly separated steps each containing identical progenitors, as previously suggested by the use 
of well-defined purification strategies. Instead, the classical stepwise differentiation routes 
emerged to be more similar to a continuous spectrum, along which cells progress in a gradual 
way from one heterogeneous population of progenitors with a certain lineage bias to another, 
and with neighbouring routes which are not sharply separated but that can potentially pour into 
each other, especially at the less committed levels. Therefore, according to this view, the 
haematopoietic tree would be better represented as a hierarchical but highly flexible continuous 






Figure 1.2 Revised representation of haematopoiesis. Based on the transcriptomics analysis of individual 
cells, the haematopoietic hierarchy appears now as a continuous spectrum. Intermediate steps are not well 
separated and the balance between distinct routes appears to be extremely fluid to adapt to blood demand 
(adapted from Laurenti and Göttgens, 2018). 
 
1.3 Ontogeny of the haematopoietic system 
 
Over the years, the developmental origin of haematopoietic stem cells has been the 
major focus of many studies, in an attempt to understand, and potentially harness for in vitro 
production, key mechanisms leading to the generation of this population, that as previously 
mentioned is of fundamental importance for regenerative medicine. 
Studies in mouse and a variety of other animal species have shown that haematopoiesis 
in vertebrate embryos occurs in distinct overlapped waves, conventionally and conveniently 
divided mainly into primitive and definitive haematopoiesis (Figure 1.3). The first wave, which 
lasts from embryonic day 7.25 (E7.25) until E9 in mouse, and equivalent to the third week of 
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gestation in human, occurs in blood islands within the yolk sac and generates the first blood 
cells of the embryo (Tavian et al., 1999). These mainly contain primitive erythrocytes, derived 
from mesodermal cells soon after gastrulation through intermediate erythroblast progenitors, 
and are substantially different from adult red blood cells, being large, nucleated cells which 
express embryonic haemoglobin proteins. This primitive wave also leads to the generation of 
low levels of macrophages and megakaryocytes.  
 
 
Figure 1.3 Haematopoietic ontogeny. During development, multiple haematopoietic waves participate in 
satisfying the emerging need of blood cells, culminating with the generation in the AGM of the first HSCs. 
These will then migrate to the foetal liver where they will expand through proliferation and with the 
contribution of HSCs from secondary haematopoietic sites. 
 
The second definitive wave starts in the yolk sac at E8.25 and produces erythro-myeloid 
progenitors (EMPs), able to generate myeloid and erythroid cells with adult features and 
functions, along with some lymphoid cells (Böiers et al., 2013; Palis, 2014; McGrath et al., 2015). 
This is later followed by the onset of intra-embryonic haematopoiesis in the aorta-gonad-
mesonephros (AGM) region of the embryo proper directly from the haemogenic endothelium 
(HE), a specialised population of endothelial cells (Tavian et al., 1996; Medvinsky and Dzierzak, 
1996; Oberlin et al., 2002). The process is marked by the appearance of intra-aortic 
haematopoietic clusters (IAHCs), groups of cells still physically associated to the haemogenic 
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endothelial cells (HECs) lining the ventral wall of the dorsal aorta in human, and on a minor 
extent the dorsal roof in mouse (Yokomizo and Dzierzak, 2010). During the process, the HECs 
progress to the haematopoietic fate to generate IAHCs through a process called endothelial-to-
haematopoietic transition (EHT). According to recent lines of investigation, EMPs generated 
at this stage are thought to be at the origin of at least part of the tissue-resident macrophages 
found in the adult (Ginhoux and Guilliams, 2016; Hoeffel, 2018). 
This definitive wave culminates at E10.5, corresponding to the fourth-fifth week of 
gestation in human, with the appearance through EHT of the first self-renewing HSCs, defined 
by their robust long-term multilineage reconstitution potential (Ivanovs et al., 2011, 2014b). 
Testimony of their endothelial origin, these cells are characterised in human by the expression 
of endothelial surface markers like CDH5, along with the typical HSC immunophenotype 
defined as CD34+/CD90+/CD38-/CD45RA-/CD45+. In addition to the AGM, other secondary 
sites have been reported to produce HSCs from the HE through EHT later on during 
development in both mouse and human, such as yolk sac, placenta, vitelline/umbilical arteries, 
and embryonic head (Ottersbach and Dzierzak, 2005; Robin et al., 2009; Li et al., 2012). Overall, 
the generation of the first HSCs is sometimes referred to as the beginning of a third 
haematopoietic wave, characterised by its high regenerative potential.  
The first HSCs are generated within IAHCs intermixed with progenitors which are 
multilineage but devoid of any reconstitution potential. Indeed, the AGM region at this stage is 
thought to contain only one to three true HSCs (Kumaravelu et al., 2002; Ivanovs et al., 2011). 
However, it is important to note that at the moment monitoring their origin relies entirely on 
functional assays, due to the current absence of unique markers defining the first HSCs. For 
this, they are operationally defined by their engraftment ability upon transplant into adult 
immunodeficient mice after intravenous injection, which might possibly be not entirely 
relevant for normal ontogeny. Indeed, the only requirement during development for early HSCs 
is to migrate to and colonise the foetal liver for further maturation, where they will only later 
acquire the competence to home to and engraft in the bone marrow. Therefore, the current 
approach might well underestimate the real number of initial cells produced by the AGM which 
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will become functional HSCs, especially in human, where this transplantation assay relies on 
suboptimal interspecies engraftment. 
Nevertheless, once generated these first HSCs migrate to the foetal liver where their 
number has been shown to dramatically increase, both as a consequence of cell proliferation 
and for the contribution of secondary haematopoietic sites (Kumaravelu et al., 2002). Starting 
from the seventh-eighth week of human gestation, the liver constitutes the main haematopoietic 
organ for blood cell production and HSC expansion and maturation until birth, time when the 
bone marrow progressively takes over this role and becomes the main haematopoietic site. 
Unfortunately, both these stages remain at the moment largely unexplored, especially in 
human.  
 
1.4 Approaches for in vitro generation of haematopoietic cells 
 
As previously mentioned (Chapter 1.2), HSCs constitute the cornerstone for the 
treatment of a variety of life-threatening diseases. Despite sensible improvements over the years 
aimed at optimising transplant efficiency to prevent rejection or reducing side effects like graft-
versus-host disease, HSC transplantation remains challenging and not always successful. 
Furthermore, the lack of immunologically matched donors is often a major obstacle. Thus, 
understating development and biology of HSCs represents an important challenge in the field 
of regenerative medicine, necessary for the implementation of new strategies to improve the 
availability and success of such treatments. However, basic studies on HSCs are technically 
difficult, especially in the human system. Primary HSCs can be obtained from bone marrow, 
umbilical cord blood or peripheral blood upon mobilisation from the bone marrow, but these 
sources are relatively rare, while the number of HSCs that can be obtained is limited (Amos and 
Gordon, 1995; Kekre and Antin, 2014). HSC expansion could provide a potential solution, and 
considerable progress has been made in defining effective culture conditions for this purpose. 
However, even the most robust protocols currently available can only achieve a modest 
expansion of HSCs in culture before losing self-renewing and engraftment ability (Kumar and 
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Geiger, 2017; Ferreira and Mousavi, 2018). Therefore, the development of alternative systems 
has become essential, in order to model human haematopoiesis to understand molecular 
mechanisms driving HSCs. Ideally, this should allow not only to improve culture conditions for 
the expansion ex vivo of primary HSCs derived from donors, but also to eventually produce 
these cells in vitro for their use in autologous transplants or for disease modelling (Vo and 
Daley, 2015).  
In this context, an advantageous alternative is provided by the use of pluripotent stem 
cells (further discussed in Chapter 1.5). These cells represent the in vitro equivalent of the 
earliest stages of embryonic development, and in the right culture conditions retain the ability 
to grow almost indefinitely and possess the capacity to differentiate to virtually every cell type 
in the body. Accordingly, over the years considerable progress has been made in developing 
methods allowing the differentiation of haematopoietic cells capable of multiple blood cell 
potential (Kaufman, 2009; Slukvin, 2013). This has been done deploying different strategies, but 
to date the generation of cells capable of long-term multilineage engraftment still remains a 
considerable challenge (Figure 1.4). 
 
 
Figure 1.4 Approaches for the artificial production of blood cells. The generation of haematopoietic cells 
in vitro has been attempted by different strategies, using differentiation and forward programming of 
pluripotent stem cells, or direct programming of somatic cells. 
 
The principal approach for the generation of haematopoietic cells in vitro using 
pluripotent cells has involved the sequential administration of small molecules and growth 
factors in a precise temporal order, in the attempt to recapitulate early events leading to the 
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generation of these cells during embryonic development. For this, a number of strategies have 
been developed. The initial use of co-cultures with mouse bone marrow stromal cells or other 
cell lines, which would ideally provide molecular signals driving haematopoietic differentiation, 
has been gradually improved towards fully feeder-free systems employing extrinsic 
manipulation of signals to mimic the in vivo environment during development (Kennedy et al., 
2007; Niwa et al., 2011; Choi et al., 2012; Sturgeon et al., 2013; Slukvin, 2013; Ramos-Mejía et 
al., 2014). Overall, these approaches have been based on the knowledge of the molecular signals 
driving natural development, knowledge that is still currently incomplete, especially in human 
where early events taking place in the AGM region are not easily accessible. For this, further 
understanding the early development of the haematopoietic system is of crucial importance, in 
order to succeed in deriving HSCs and other blood products which are fully functional and 
suitable for translational applications. On this note, a more comprehensive approach 
complementing in vivo and in vitro studies will possibly represent the best strategy to fill the 
gaps in the current knowledge on human haematopoietic ontogeny. 
An alternative strategy has involved bypassing the normal developmental route by 
directly enforcing the expression of transcription factors leading to the desired cell types, HSCs 
or other blood products. This approach has been used in pluripotent stem cells (forward 
programming) and somatic cells (direct programming), and consists in the direct conversion 
of the source cell type to another through activation of the correct transcriptional machinery  
(Elcheva et al., 2014; Easterbrook et al., 2016). This method has been proved to be promising, 
especially for what concerns the production of mature cell types to be used directly for 
transfusions (Moreau et al., 2016). Nonetheless, a few challenges are still remaining, including 
immunocompatibility, low-throughput of the process, and full functionality of the product in 
vivo. Importantly, this strategy has been recently employed to successfully convert mouse adult 
vascular endothelial cells towards the generation of immunocompetent HSPCs (Lis et al., 2017). 
For this, purified endothelial cells were transduced to obtain the expression of four 
transcription factors (FOSB, GFI1, RUNX1 and SPI1), followed by co-culture with human 
umbilical vein endothelial cells modified to express the E4ORF1H gene. This approach was able 
to convert the isolated endothelial cells to multipotent HSPC-like cells capable of long-term 
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engraftment. Of note, a similar result was accomplished by using both the methods described 
above, thus combining hPSC differentiation and direct programming (Sugimura et al., 2017). 
For this, hPSCs were initially directed through stepwise administration of morphogens to the 
generation of haemogenic endothelial cells. These cells were then infected to obtain the viral-
mediated expression of seven transcription factors (ERG, HOXA5, HOXA9, HOXA10, LCOR, 
RUNX1 and SPI1) identified by screening of a bigger library. The resulting cells were capable 
of multilineage engraftment in primary and secondary mouse recipients.  
Despite allowing the generation of HSPC-like cells in vitro, both these methods still 
retains features which make them not amenable for clinical application, namely the difficulty 
of obtaining large-scale production of these cells and the requirement for viral transgene 
expression. Nevertheless, they undoubtedly sheds lights on the molecular requirements 
necessary for the successful generation of HSCs in vitro.    
 
1.5 Pluripotent stem cells as a model of early development and 
a promise for regenerative medicine 
 
As anticipated in the previous section, human pluripotent stem cells represent a potential 
alternative solution to the study of molecular mechanisms taking place during haematopoietic 
development and for the generation in vitro of cells for their use in cell therapy, disease 
modelling and regenerative medicine. In this context, a major breakthrough in the field was the 
establishment of culture techniques for the expansion and maintenance ex vivo of the first 
pluripotent stem cells, embryonic cells derived from the mouse blastocyst (Evans and Kaufman, 
1981; Martin, 1981). This was followed by years of efforts aimed at obtaining similar cells in 
human, which ultimately led to the derivation of the first human embryonic stem cells (hESCs; 
Thomson et al., 1998). For this, cells were cultured from the inner cell mass of pre-implantation 
blastocysts, obtained from surplus embryos for in vitro fertilisation procedures. These cells were 
characterised by self-renewal ability and importantly pluripotency, defined as the capacity to 
differentiate towards the three embryonic germ layers, namely endoderm, mesoderm and 
36 
neuroectoderm, therefore with the potential of generating every cell type in the human body 
(Figure 1.5). They represented a simplified model for human development, and allowed to study 
mechanisms otherwise difficult or even impossible to access in vivo. Furthermore, the 
development of protocols for the differentiation of mature cell types with adult phenotype 




Figure 1.5 Human pluripotent stem cells. hESCs derived from the inner cell mass of pre-implantation 
blastocyst and hIPSCs generated by reprogramming of somatic cells are the in vitro equivalent of the earliest 
stages of human development. They retain self-renewal ability and pluripotency, and can potentially be used 
to generate every cell type of the human body. 
 
However, the large-scale production of hESC lines remained a considerable challenge, 
mainly because of the paucity of human embryos donated for research purposes. Furthermore, 
the use of hESCs for research and potentially for treatments raised ethical concerns about the 
use of human embryos (McLaren, 2001). This led for example in the United States of America 
to an almost complete ban of federal funding for hESC research, which only recently has been 
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partially lifted (Holden, 2009). Importantly, the derivation of these cells is still illegal in some 
countries, one example being Italy (Frassoni, 2006; Palazzani, 2011). These concerns and 
limitations were finally overcome by the development of techniques showing that adult somatic 
cells could be reprogrammed in both mouse and human to an embryonic-like state by the 
introduction of specific transcription factors (Takahashi and Yamanaka, 2006; Takahashi et al., 
2007). Specifically, the first human induced pluripotent stem cells (hIPSCs) were obtained by 
viral-mediated overexpression of the four transcription factors OCT4, SOX2, KLF4 and c-MYC 
in adult fibroblasts obtained through biopsy. Over the years, this approach has been extensively 
refined in order to improve reprogramming efficiency, allow the process to be carried out on 
different and more accessible cell types, and also to avoid the integration of transgenes by 
performing transfection and transient expression of the factors using non-integrating vectors 
(Hochedlinger and Jaenisch, 2015). Importantly, these cells were shown to share most of the 
hESC properties and to be capable of self-renewal and differentiation through the three germ 
layers. For this, both hESCs and hIPSCs are now collectively referred to as human pluripotent 
stem cells (hPSCs; Figure 1.5). 
These cells offer the unprecedented opportunity to model the earliest stages of human 
development, confirming and complementing studies involving the use of animal models. 
Additionally, the capacity of these cells to differentiate offers the possibility to deepen our 
understanding of events taking place later on during development in specific tissues or organs 
of not immediate access, one example being the onset of definitive haematopoiesis. 
Furthermore, hIPSCs hold great promise for regenerative medicine. They represent a virtually 
unlimited source of patient-derived immunologically matched cells, to be used for 
transplantation, with the perspective of regenerating damaged tissues or whole organs thus 
avoiding immunosuppression. Moreover, hIPSCs derived from patients with genetic disorders 
allow disease modelling and potentially the development of treatments based on the study of 
mechanisms that are not always conserved in animal models.  
However, for all these applications, understanding signalling pathways and molecular 




1.6 Signalling pathways controlling pluripotency 
 
The first stages of hPSC research involved considerable efforts aimed at determining 
conditions that would allow the long-term maintenance of these cells in culture in an 
undifferentiated state. Initial attempts led to the use of co-culture systems on feeder layers of 
mitotically inactivated mouse embryonic fibroblasts (MEFs), which were shown to provide 
factors able to maintain pluripotency. In this system, hPSCs could be detached from the feeder 
layer and then induced to differentiation as floating clumps of cells in the presence of serum. 
The lack of pluripotency-inducing factors and the presence of serum were able to induce the 
formation of 3D structures generating cells of the three germ layers, and were thought to 
partially approximate the complexity of the early embryo (Itskovitz-Eldor et al., 2000). For this, 
they were called embryoid bodies (EBs). Despite MEF cultures and EB differentiation represent 
still today valuable tools for specific applications, stem cell research over the years has been 
characterised by the attempt at identifying robust feeder-free, chemically defined conditions for 
the maintenance and differentiation of hPSCs  (Wiles and Johansson, 1999; Chen et al., 2011).  
These technical improvements had to be accompanied with the identification and an 
increasingly deeper understanding of signalling pathways controlling pluripotency. Notably, 
culture conditions that had been described for mouse embryonic stem cells did not prove 
successful in maintaining pluripotency in feeder-free hESC cultures. It was indeed later 
demonstrated that the two stem cell models represented distinct stages of embryonic 
development, corresponding to distinct states of pluripotency and characterised by unique 
signalling requirements (Pauklin et al., 2011). 
 
1.6.1 Activin/NODAL/TGFβ signalling 
 
Ultimately, the feeder-secreted factors responsible for the maintenance of hESC 
pluripotency in culture were demonstrated to be molecules of the TGFβ superfamily (Vallier et 
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al., 2004). Indeed, the addition of Activin, NODAL or TGFβ were able not only to promote 
pluripotency, but also to inhibit the default differentiation pathways leading to neuroectoderm 
(Vallier et al., 2005). Of note, Activin and NODAL, which bind to the same receptor, are 
functionally very similar to TGFβ, all of them activating the same downstream effectors SMAD2 
and SMAD3 (Figure 1.6). As a result, these are phosphorylated and activated, enter the nucleus 
and induce transcription of their target genes, which include genes controlling pluripotency 
and differentiation (Pauklin and Vallier, 2015). One of the fundamental factors controlled by 
this pathway is NANOG, a master regulator of pluripotency which at the same time interacts 
with SMAD2/3 and guides their binding to key genomic locations to further reinforce the 
pluripotency transcriptional network (Brown et al., 2011). SMAD2/3 and NANOG have also 
been shown to cooperate for the recruitment of methyltransferases that leads to the deposition 
of epigenetic marks like H3K4me3 on key developmental genes for the maintenance of the 
pluripotent state (Bertero et al., 2015). Furthermore, SMAD2/3 has been recently shown to 
participate in an additional layer of complexity in the regulation of pluripotency, by interacting 
with the METTL3-METTL14-WTAP methyltransferase complex and controlling the m6A 
modification of a subset of transcripts involved in early cell fate decisions, therefore priming 
them for rapid downregulation upon commitment and differentiation (Bertero et al., 2018). 
Overall, the Activin/NODAL/TFGβ pathway appears to be a fundamental driver of 
pluripotency and a requirement for the maintenance of the undifferentiated state, while their 
inhibition results in differentiation, preferentially towards the default neuroectoderm lineage.  
 
1.6.2 FGF signalling 
 
In addition to this key pathway, FGF2 was also shown to have an important role in 
hESCs, working synergistically with the Activin/NODAL/TGFβ signalling to maintain the 
undifferentiated state (Vallier et al., 2005). The interaction of FGF2 with its receptors can result 
in the activation of four distinct signalling pathways, namely the JAK/STAT, PLCγ, PI3K and 
MAPK/ERK pathways (Dailey et al., 2005; Lanner and Rossant, 2010). Of these, the MAPK/ERK 
pathway, and to a lesser extent the PI3K pathway, have been extensively explored. Specifically, 
40 
the MAPK/ERK pathway involves the sequential phosphorylation and activation of RAF, MEK 
and ERK1/2 kinases, which shuttles to the nucleus and activate downstream proteins leading to 
the induction of target genes (Figure 1.6). Studies have also shown that FGF signalling 
contributes to the expression of NANOG (Greber et al., 2007). Interestingly, FGF alone is not 
sufficient for the maintenance of pluripotency, and instead it appears to be working 
synergistically with the Activin/NODAL/TGFβ signalling by increasing the expression of 
NODAL co-factor CRIPTO (Vallier et al., 2005). Furthermore, ERK2 has been reported to 
interact with multiple genomic loci in hESCs, involved in a number of functions like 
metabolism, cell cycle progression and pluripotency (Göke et al., 2013). Ultimately, FGF 
signalling appears to trigger a variety of biological responses, involved in proliferation, cell 
survival and differentiation of hPSCs. Importantly, Activin/NODAL/TFGβ and FGF2 have 
been shown to maintain pluripotency also in hIPSCs, confirming these cells to be functionally 
equivalent to hESCs (Vallier et al., 2009).   
Of note, other factors also participate in maintaining pluripotency. The IGF signalling 
pathway has been shown to be partially redundant with FGF, and activate the PI3K pathway 
resulting in increased cell proliferation and inhibition of differentiation (Campbell et al., 2012). 
At the same time the WNT canonical pathway (further discussed in Chapter 1.7.1), acting 
through the effector β-catenin, is also important for hPSCs, with its role depending on the 
signalling strength. Indeed, low levels of WNT activation promote the pluripotent state, while 
stronger stimulation leads to mesendoderm specification (Sumi et al., 2013). Importantly, the 
undifferentiated state appears to be maintained through an extensive crosstalk between these 
multiple signalling pathways (Singh et al., 2012). 
Remarkably, these molecular requirements closely recapitulate signalling pathways with 
a key role in the post-implantation mouse embryo, in which NODAL is necessary to maintain 
the expression of pluripotency markers in the epiblast (Camus et al., 2006). On one side, this 
further underlines the importance of understanding early development for the correct 
manipulation of pluripotency and differentiation in vitro, and on the other it confirms the 
potential of hPSCs in allowing fateful modelling of human development. 
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Figure 1.6 Signalling pathways maintaining pluripotency. Activin/NODAL/TGFβ and FGF are the main 
signalling pathways driving pluripotency. These also synergise with other pathways such as IGF and WNT. 
 
 
1.7 Signalling pathways driving haematopoietic differentiation 
 
Initial methods for the in vitro differentiation of hPSCs relied on the use of serum in the 
culture media, whose composition was undefined and included factors which drove 
commitment at least partially in an uncontrolled way. Over the years, several studies led to the 
identification of fundamental molecular pathways driving early germ layer specification and 
commitment to differentiated cell types. The knowledge derived from developmental studies 
allowed for the progressive development of more refined culture conditions for the 
differentiation of hPSCs in vitro through early germ layers to more differentiated cell types, in 
an accurately guided manner, whose rationale was the faithful recapitulation of developmental 
mechanisms (Murry and Keller, 2008). Of note, recapitulating haematopoietic development in 
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vitro also requires the tight control of early germ layer induction, specifically towards the 
generation of the lateral plate mesoderm subtype which developmentally undergoes 
haematopoietic specification in vivo (Dzierzak and Bigas, 2018). 
From these developmental studies, it was soon recognised that FGF and most importantly 
the Activin/NODAL/TGFβ signalling are not only master gatekeepers of pluripotency, but have 
also a fundamental role during early germ layer specification. This dual action depends on the 
crosstalk with other key signalling pathways such as BMP and WNT, and notably their relative 
manipulation in vitro drives both early mesendoderm/neuroectoderm specification and 
mesoderm subtype patterning in hPSCs (Bernardo et al., 2011; Mendjan et al., 2014; Faial et al., 
2015). Indeed, the same pathways regulating pluripotency appear to also control a complex 
process like gastrulation that in vivo results from the relative position along the embryo 
exposing distinct cells to specific levels of agonists and inhibitors, whose expression forms a 
gradient along the anteroposterior axis (Figure 1.7). This drives the interplay between different 
pathways, and ultimately determines cell fate decision and differentiation (Tam and Behringer, 
1997; Murry and Keller, 2008).  
Consequently, the recapitulation of this positional effect is necessary for the control of 
germ layer induction in vitro, which relies on the accurate combination of signalling molecules. 
As already mentioned, the role of Activin/NODAL/TGFβ and FGF during differentiation 
depends on their crosstalk with BMP and WNT pathways (Mendjan et al., 2014; Faial et al., 
2015). Indeed, by modulating the dosage of these signalling pathways it is possible to obtain 
mesendoderm and induce different subtypes of mesoderm, characterised by distinct potential 








Figure 1.7 Positional effect during embryonic development. The relative position along the 
anteroposterior axis determines the level of activation of distinct signalling pathways and the extent of their 
crosstalk. This positional effect needs to be fatefully recapitulated in vitro for the generation of the correct germ 
layer able to differentiate towards a certain somatic cell type. 
 
1.7.1 WNT signalling 
 
As already mentioned, the WNT canonical pathway leads to the accumulation and 
nuclear translocation of β-catenin, which functions as a transcriptional co-activator for a 
number of target genes. For this, WNT binding to its heterodimeric receptor composed of 
Frizzled and LRP5/6 proteins leads to the disruption of an intracellular protein complex 
including Axin, APC and GSK3, by causing its translocation to the plasma membrane (Figure 
1.6). In WNT absence, the complex phosphorylates and marks for degradation the effector β-
catenin. But upon WNT activation, this degradation activity is inhibited, leading to β-catenin 
accumulation in the cytoplasm and its translocation into the nucleus, where it leads to the 
activation of its target genes (Clevers and Nusse, 2012).  
Beyond this, WNT also signals through non-canonical pathways that do not involve β-
catenin. These include the planar cell polarity pathway, which regulates the cytoskeleton, and 
the calcium pathway, which regulates intracellular calcium levels. Both these pathways rely on 
the interaction of WNT ligands with the same heterodimeric Frizzled-LRP5/6 receptor, which 
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intracellularly binds to Dishevelled (DSH; Komiya and Habas, 2008). More specifically, for the 
planar cell polarity pathway, DSH on one side associates with DAAM1 and activate the protein 
Profilin, able to bind Actin, and the small G protein Rho which activates ROCK, a major 
cytoskeleton regulator. On the other side, DSH can signal to RAC1, which activates JNK, 
leading to its action on target genes. These events result in the restructuring of the cytoskeleton, 
important, for example, during gastrulation. The other non-canonical pathway is the calcium 
pathway, in which Frizzled not only activates the intracellular DSH, but also interact with a 
trimeric G protein. Ultimately, this signalling results in calcium release from the endoplasmic 
reticulum, which then leads to the activation of proteins like Calcineurin, that in turn activates 
factors such as NFAT, involved in embryonic ventral patterning, and in the control of cell 
adhesion, migration and tissue separation. 
For in vitro directed differentiation of hPSCs, the activation of WNT signalling during 
an early stage has been reported to be associated with an enrichment in progenitors of the 
definitive haematopoietic wave. Importantly, this has been achieved through CHIR99021, a 
small molecule inhibiting GSK3 and therefore leading to β-catenin accumulation, suggesting 
that WNT canonical pathway is necessary for the generation of lateral plate mesoderm 
contributing to definitive haematopoiesis (Sturgeon et al., 2014). Furthermore, studies 
performed in mouse have shown the pathway to be transiently required for HSC specification 
in the AGM, but not for their subsequent maintenance (Ruiz-Herguido et al., 2012). 
 
1.7.2 BMP signalling 
 
BMPs are secreted extracellular matrix-associated proteins of the TGFβ superfamily, 
important for a wide range of processes during development. An important role in the BMP 
signalling regulation is played by the secretion of antagonists like Noggin, able to bind BMP 
members and therefore inhibit the association with their receptor counterparts. Both these 
groups of molecules are associated with the extracellular matrix in order to limit their effect on 
neighbouring cells. Upon binding, BMP causes the dimerization of its receptor subunits BMPRI 
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and BMPRII, leading to intracellular phosphorylation of SMAD1, SMAD5 and SMAD8. These, 
in association with the cofactor SMAD4, translocate into the nucleus and activate the expression 
of their target genes (Wang et al., 2014; Brazil et al., 2015). In addition to the canonical 
BMP/SMAD signalling, other non-canonical roles have been described, including for example 
the activation of MAPK signalling, or the interaction with PI3K and Rho GTPases. Of note, the 
balance between canonical and non-canonical functions is likely to depend on the extracellular 
environment and the cellular context  (Wang et al., 2014a). 
It is important to note that an extensive crosstalk exists between the BMP signalling and 
other pathways. Remarkably, differentiation cultures using hPSCs in the presence of different 
levels of BMP4, Activin, FGF2, the WNT inhibitor CHIR99021 and the PI3K inhibitor 
Ly294002, have been shown to generate distinct mesendoderm subtypes (Figure 1.7). This is 
achieved through a finely tuned interaction between key downstream effectors like SMADs, 
pluripotency regulators like NANOG and early key mesendoderm factors such as 
BRACHYURY, which collectively directs the earliest stages of embryonic development 
(Mendjan et al., 2014; Faial et al., 2015).  
BMP signalling has also been known to have a role in promoting the generation of 
haematopoietic cells from the AGM region (Durand et al., 2007). However, its effect seems to 
be dependent on modulation by other pathways like FGF (Pouget et al., 2014), and its activation 
appears to be tightly regulated by a temporal and spatial balance between ligands like BMP4 
and antagonists like BMPER (McGarvey et al., 2017). BMP activation is indeed needed for the 
initial HSC specification, but its subsequent inhibition seems to be equally necessary for the 
successful maturation of functional HSCs (Souilhol et al., 2016). Furthermore, beyond its 
importance for haematopoietic emergence in the dorsal aorta, its role later during development 
is still not entirely clear, since foetal liver HSCs show heterogeneity in their ability to respond 




1.7.3 Notch signalling 
 
Notch signalling is a highly conserved pathway in which both the receptors and their 
ligands are usually transmembrane proteins, therefore allowing for short-range communication 
and requiring physical contact between neighbouring cells. It plays a critical role during 
development, resulting in a response that is context-dependent and can promote or suppress 
proliferation, cell death, fate decision and differentiation. A distinguishing hallmark of Notch 
signalling is its transduction mechanism. Indeed, it relies on the proteolysis of the Notch 
receptor upon binding to its ligand, which produces an active Notch intracellular domain 
(NICD). Once released, the NICD fragment shuttles to the nucleus where it binds to other 
transcription co-factors and activates its target genes (Kopan and Ilagan, 2009).  
The Notch pathway is particularly important in angiogenesis and blood development. 
In HECs undergoing EHT, Notch signalling guides the generation of IAHCs, and this action 
seems to depend on a NOTCH1-dependent induction of key haematopoietic factors such as 
RUNX1 and GATA2 (Kumano et al., 2003; Burns et al., 2005; Guiu et al., 2013; Ditadi et al., 
2015). Furthermore, it was recently reported that pivotal to the correct induction of the 
haematopoietic programme is the strength of such signalling. It was indeed shown that in 
endothelial cells in the mouse dorsal aorta, the distinct arterial and haemogenic programmes 
rely on the induction by the two Notch ligands DLL4 and JAG1, respectively (Gama-Norton et 
al., 2015). Both ligands are expressed in the dorsal aorta, but binds to NOTCH1 with a different 
affinity and activate their signal with different strength. The stronger NOTCH1/DLL4 
signalling results in the activation of the arterial programme, but this interaction is 
outcompeted by JAG1, which has a higher affinity for the receptor. This results in a preferential 
NOTCH1/JAG1 signalling which possesses weaker strength, and which blocks the arterial 
programme and activates instead haemogenic specification.  
Notably, a strong Notch signalling induction by DLL4 seems to also drive terminal 
haematopoietic maturation, as shown by studies using co-culture systems with mouse stromal 




1.7.4 Importance of integrating multiple pathways 
 
The emergence of the first HSCs is a complex process, carefully regulated by the 
interaction between multiple gradients of molecules on the dorsoventral axis, along with signals 
coming from the lateral urogenital ridges (Figure 1.8). The aforementioned FGF, WNT and 
BMP signalling pathways indeed show extensive crosstalk with other pathways. An example is 
given by an important inducer of HSC emergence in the AGM such as sonic hedgehog (SHH; 
Gering and Patient, 2005; Peeters et al., 2009). Despite this being produced dorsally from the 
notochord, the dorsal roof of the aorta has a much lower sensitivity to SHH compared to the 
ventral portion, explaining the emergence of IAHCs preferentially (in mouse) or exclusively (in 
human) from this area. Furthermore, the two opposite dorsal SHH and ventral BMP gradients 
appear to feedback on each other. It was indeed suggested that BMP acts initially in the 
induction of the haematopoietic programme, and carefully regulates the intensity of SHH 
signalling by inhibiting its expression. However, BMP signal needs to be turned off to complete 
HSC emergence, and SHH appears indeed to increase the expression of Noggin which 
antagonises BMP while at the same time increasing SHH expression itself, overall delineating 
an important cross-regulation between the two pathways causing a transient BMP activation 
(Wilkinson et al., 2009; Souilhol et al., 2016). 
Another example of signalling pathways interacting to regulate haematopoietic 
development is given by WNT signalling, that as previously mentioned was shown to be 
necessary for HSC specification, but not for their maintenance (Ruiz-Herguido et al., 2012). It 
appears that this temporal regulation might be associated with the action of other signalling, 
mediated by retinoic acid. This signal was previously suggested to be necessary for 
haematopoietic specification (Goldie et al., 2008), and it appears that for this effect to take place, 
WNT signalling needs first to be downregulated. Furthermore, it was suggested that retinoic 
acid itself might actually inhibit WNT signalling (Chanda et al., 2013). As a result, WNT is 
inhibited in emerging haematopoietic cells, and its activation remains limited to the 
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surrounding endothelium, as shown in the mouse AGM by the presence of β-catenin in 
endothelial cells but not in IAHCs.  
Additionally, the Notch signalling has been reported to crosstalk with VEGF, one of the 
main signals controlling angiogenesis. During vascularisation, endothelial cells growth is 
stimulated by the action of VEGF signalling, whose gradient guides their migration and 
proliferation. At the same time, VEGF is able to induce the expression of DLL4. The resulting 
interaction of DLL4 with NOTCH1 counterbalances endothelial growth by inhibiting the 
expression of VEGF receptors and therefore reducing endothelial cell responsiveness to this 
growth signal. Coherently, lack of Notch signalling results in uncontrolled endothelial 
migration and proliferation (Hellström et al., 2007; Leslie et al., 2007; Siekmann and Lawson, 
2007). While this mechanism seems to be important during vascularisation, its role in HSC 
specification is still to be fully elucidated, despite a certain level of interaction taking place 
during EHT, in which VEGF function appears to be upstream of the Notch pathway (Leung et 
al., 2013).  
 
Figure 1.8 Signalling pathways driving EHT. The interplay between multiple pathways along the 
dorsoventral axis determines the emergence of haematopoietic cells in the dorsal aorta (IAHCs: intra-aortic 
haematopoietic clusters; HECs: haemogenic endothelial cells; VECs: vascular endothelial cells). 
 
Furthermore, interaction with Notch signalling and a role during haematopoietic 
development was also suggested for inflammatory signals. IFNγ was indeed shown to promote 
HSC emergence in zebrafish embryos, and the expression of this signal was suggested to be 
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downstream of Notch (Sawamiphak et al., 2014). Simultaneously, another inflammatory signal 
like TNFα was also shown to directly upregulate the expression of JAG1, and therefore increase 
HSC production through promotion of Notch signalling (Espín-Palazón et al., 2014). 
Interestingly, this last finding is in agreement with the previously mentioned study showing the 
specific role of the NOTCH1/JAG1 pathway in promoting EHT (Gama-Norton et al., 2015). 
Further work is needed to fully elucidate the role of inflammatory signals on HSC generation, 
but it has been suggested from zebrafish studies that these signals might come from primitive 
macrophages, which in sterile conditions and in the absence of infection contribute to the 
events that in the developing embryo lead to adult haematopoiesis, therefore delineating a more 
complex pro-definitive role for the primitive haematopoietic wave.  
 
1.7.5 TAL1, RUNX1 and GATA2: master regulators of haematopoiesis 
 
Gradients of signal molecules drive multiple developmental events in different parts of 
the embryo. Their combination leads to the sequential activation of the lateral plate mesoderm, 
the endothelial and the haematopoietic programme. This ultimately relies on multiple 
transcription factors that are involved in HSPC specification, but also in their maintenance and 
lineage commitment. The diversity of roles for the same factors depends on their highly 
context-dependent activity, which indeed varies according to the presence of other co-factors 
guiding the expression of target genes. Multiple transcriptional complexes drive the 
haematopoietic fate, and although many of the individual players in these complexes have been 
identified and characterised, their activity and functioning still need to be fully elucidated. 
Three of the main factors known to drive HSPC specification and with a diversity of roles during 
haematopoiesis are the master regulators TAL1, RUNX1 and GATA2. 
TAL1 is a transcription factor that in combination with VEGF signalling is able to 
inhibit the cardiac lineage in early mesoderm, specify lateral plate mesoderm towards 
haematopoietic and endothelial fates, and subsequently consolidate the haematopoietic fate 
(Org et al., 2015). TAL1 expression is induced by a combination of VEGF and BMP signalling. 
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It is a strong inducer of HSPC specification, but it is present at every level of the haematopoietic 
hierarchy, being involved in the onset of haematopoiesis, in HSPC maintenance and in lineage 
commitment. Its action is indeed strongly context-dependent, and for example can induce 
HSPC emergence when in combination with GATA2, or erythroid and megakaryocytic 
differentiation when combined with GATA1 (Shivdasani et al., 1995;  Hoang et al., 2016; 
Vagapova et al., 2018). Interestingly, TAL1 was also shown to control adult HSC entry into the 
cell cycle. Its expression in mouse is indeed higher in adult LT-HSCs compared to ST-HSCs, 
and it can keep the stem cell pool in quiescence by activating the expression of genes such as 
the cell cycle inhibitor CDKN1A/p21 (Lacombe et al., 2010).  
Differently from TAL1, RUNX1 is not required during the primitive haematopoietic 
wave, but its deletion prevents instead endothelial cells from undergoing EHT and generating 
IAHCs. This results in a complete loss of definitive blood cells, highlighting RUNX1 specific 
requirement for the activation of the definitive haematopoietic programme (Okuda et al., 1996; 
Cai et al., 2000). The observation that RUNX1 is expressed in a small population of endothelial 
cells where IAHCs will subsequently emerge, therefore anticipating their appearance, gave a 
first confirmation for the endothelial origin of the definitive haematopoietic wave (North et al., 
1999). Overall, RUNX1 appears to be fundamental for EHT and the generation of definitive 
EMPs and HSPCs, but not for the differentiation of early mesodermal progenitors into 
primitive haematopoietic cells. Furthermore, its requirement has been suggested to end once 
the HSPC programme has been specified in the AGM (Chen et al., 2009). Nevertheless, RUNX1 
continues to be expressed thereafter, and mutations in its gene are often associated with 
leukaemia  (Ichikawa et al., 2013), suggesting that RUNX1 subsequent role still needs to be fully 
understood. Indeed, despite RUNX1 having been the focus of many studies, its downstream 
effectors and the molecular mechanisms of its action still remain largely unknown. One 
important effect mediated by RUNX1 is the upregulation in the HE of the two transcription 
factors GFI1 and GFI1B, which play an important role in repressing endothelial genes while 
RUNX1 activates the haematopoietic programme (Lancrin et al., 2012).  
A third master regulator of haematopoietic development is GATA2. This factor is not 
strictly required for primitive haematopoiesis. Despite being expressed, its absence causes only 
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a modest effect, and it was indeed shown that at this stage GATA2 functionally overlaps with 
GATA1, the main factor driving primitive erythropoiesis along with TAL1 (Fujiwara et al., 
2004). GATA2 is instead necessary for the specification of definitive haematopoiesis, being 
expressed in HECs and IAHCs and with its absence preventing EHT (de Pater et al., 2013). The 
expression of GATA2 was reported to be directly controlled by NOTCH (Robert-Moreno et al., 
2005). Importantly, GATA2 is not only required for the generation of HSCs in the AGM, but is 
also important for their maintenance thereafter. This role requires GATA2 levels to be 
maintained within stringent levels, as both downregulation and overexpression of this factor 
are associated with disease and leukaemia (Ostergaard et al., 2011; Luesink et al., 2012; Vicente 
et al., 2012).  
Importantly, a complex crosstalk between RUNX1, TAL1 and GATA2 was shown to be 
mediated by BMP signalling. Specifically, the BMP effector SMAD1 was reported to upregulate 
both RUNX1 and GATA2. The latter, in a complex with TAL1 and FLI1, can reinforce this 
signal by upregulating SMAD1/5, but also upregulate SMAD6 which represses RUNX1, 
therefore constituting a complex circuit for the temporal and balanced activation of RUNX1 
(Oren et al., 2005; Marks-Bluth et al., 2015). Remarkably, RUNX1 was also shown to bind TAL1, 
causing a global reorganization of its genomic binding pattern, perhaps important for the shift 
of TAL1 role from the primitive to the definitive haematopoietic programme (Lichtinger et al., 
2012). Furthermore, ChIP-sequencing experiments show that RUNX1, GATA2 and TAL1 are 
often found together in association at genomic sites (Wilson et al., 2010). Overall, these findings 
delineate a finely tuned crosstalk between these three master regulators of haematopoiesis, 
whose expression and role are finely controlled, change during development and are highly 
context-dependent.   
 
1.8 Cell cycle 
 
The cell cycle involves all the events leading to DNA duplication and cell division in order 
to produce two daughter cells, and it is therefore one of the most fundamental molecular 
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mechanisms. However, its role extends beyond cell growth and division, as it is also associated 
with other fundamental processes such as DNA repair, morphogenesis and cell fate decision. 
As such, dysregulations in the control of the cell cycle can lead to aberrant proliferation and 
cancer. Importantly, cell cycle regulation and key components of its molecular machinery have 
been proven to drive haematopoietic development and homeostasis.  
 
1.8.1 Cell cycle phases 
 
The cell cycle is commonly divided into interphase and mitotic phase. Interphase 
involves a variety of biochemical processes that prepare the cell for division happening during 
mitosis. The various stages of interphase are usually not morphologically distinguishable. 
Nevertheless, it can be further divided into G1 (gap 1), S (synthesis) and G2 (gap 2) phases, each 
characterised by distinct biochemical processes, and together with the M (mitosis) phase they 
constitute the most common subdivision in four consecutive cell cycle phases (Schafer, 1998).  
The main events characterising cell cycle are DNA replication, taking place during S 
phase, and cell division, in M phase, both of them complex processes characterised by high 
fidelity and quality controls to ensure the correct generation of two daughter cells, and with 
safeguard mechanisms that allow DNA repair upon duplication errors or to get rid of cells with 
an abnormal chromosomal asset. The remaining gap phases are essentially preparation stages 
making sure everything is in place for the subsequent events, but also checkpoints integrating 
different signals to determine cell cycle progression or arrest. Specifically, the G1 phase involves 
most of the biosynthetic activity of the cell, resumed immediately after the previous division, 
and consisting of protein synthesis, increase in number of organelles and growth in cell size. 
This phase includes key control mechanisms making sure that everything is ready for DNA 
duplication, but also linking the cell cycle state to the external environment. Indeed, these 
control mechanisms collectively constitute checkpoints, or restriction points, representing 
moments determining if the cell will proceed into the S phase, remain in G1 until specific 
conditions apply such as growth signals or nutrients availability, or exit the cell cycle and enter 
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a longer reversible quiescent state also known as G0. In this context, it is important to note that 
adult HSCs are well known to mostly reside in G0, and to only re-enter the cell cycle when 
needed in order to satisfy blood demand.  These checkpoints are of fundamental importance, 
as once the cell enters the S phase, it is usually committed for cell division. As such, the duration 
of G1 is highly variable, and dependent on developmental stage, cell type and external 
conditions. The G2 phase occurs instead immediately after DNA duplication and corresponds 
to a period of rapid growth, protein synthesis and early microtubule reorganization, events that 
are necessary for the subsequent mitosis.  
 
1.8.2 Cyclins and CDKs  
 
Cell cycle progression needs to be tightly regulated, on one side to detect and repair 
DNA lesions and ensure that daughter cells inherit the correct genetic material; on the other to 
prevent uncontrolled proliferation which would disrupt tissue homeostasis and ultimately lead 
to cancer. Two classes of molecules are responsible for this regulation, functioning as both 
checkpoints for the progression into the subsequent cell cycle phase, and integrating the 
complexity of the signalling pathways instructing cell proliferation. These regulators are cyclins 
and cyclin-dependent kinases (CDKs), and include several members that function as a complex 
in specific combinations during distinct cell cycle phases. In these complexes, the CDKs 
constitute the effector subunits, having phosphorylation activity upon binding to their specific 
cyclins, which are instead the regulatory subunits. Specific cyclin-CDK complexes are activated 
at distinct cell cycle phases. The CDKs are usually constitutively expressed, while cyclin levels 
change in a periodic way and, upon expression, they bind to their CDK partner and allow cell 
cycle progression, for example inducing the expression of target genes (Figure 1.9). The specific 
downstream effect depends on the cyclin-CDK combination (Schafer, 1998).  
Signals promoting cell cycle progression such as growth factors, induce the expression 
of D cyclins during G1 which bind to CDK4 and CDK6. The cyclin D-CDK4/6 complex 
phosphorylates and inactivates the transcriptional repressors of the Rb family, consisting of 
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RB1, RBL1/p107 and RBL2/p130. These proteins restrict cell cycle entry and maintain the cell 
in G1 by binding and repressing E2F, thus preventing the activation of genes involved in cell 
cycle progression. Upon phosphorylation by cyclin D-CDK4/6, the Rb members are partially 
inactivated and E2F activates the transcription of genes necessary for the transition to the next 
phase, like cyclin Es and cyclin As. As a result, cell cycle progresses through G1. In late G1, 
additional phosphorylation by the now active cyclin E-CDK2 complex further inactivates the 
Rb-mediated inhibition of E2F, resulting in a complete G1 exit and entry into the S phase. At 
this stage, cyclin A-CDK2 is the main active complex, which induces the expression of proteins 
involved in DNA replication and drives the further transition through the S phase. Once 
accumulated, cyclin As also bind to CDK1, and the cyclin A-CDK1 complex starts the G2/M 
transition. During G2 there is also expression of cyclin Bs, whose peak happens slightly later 
compared to cyclin As. The resulting cyclin B-CDK1 complex further promotes the G2/M 
transition, subsequently causing the breakdown of the nuclear envelope and promoting mitosis 
during M phase (Poon, 2016).  
 
Figure 1.9 Cell cycle regulation. The dynamic expression of regulatory cyclins is responsible for the timely 
activation of specific CDKs and for the progression through successive cell cycle phases. 
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The machinery directing cell cycle progression is tightly regulated, not only by the 
temporal upregulation of cyclins but also by other factors which can inhibit cyclin-CDK 
complexes, especially during G1, when the commitment to enter cell cycle is established. 
Beyond the aforementioned Rb proteins, many other factors contribute to this tight regulation. 
One example are the members of the INK4 family, that include p16, p15, p18 and p19, and 
whose role is to block CDK4/6 and thus restrict cells in G1. Other key CDK inhibitors are the 
proteins of the CIP/KIP family p21, p27 and p57, which can inhibit both CDK4/6 in G1 and 
CDK2 in S phase. These and other factors contribute to drawing the complex regulatory 
landscape that determines cell cycle progression or arrest (Pietras et al., 2011). 
Remarkably, increasing evidence over the years has shown a variety of non-canonical 
functions for both cyclins and CDKs. Direct kinase-independent transcriptional roles were for 
example reported for G1 cyclins and CDKs. Indeed, Cyclin D1 can directly bind to and inhibit 
p300 and CBP, therefore inhibiting their acetyltransferase activities and repressing various 
promoters (McMahon et al., 1999). Importantly, during haematopoietic differentiation both 
cyclin D3 and CDK6 can instead individually interact with RUNX1 and reduce its ability to 
bind to DNA and activate target genes. This activity does not require binding to their partner 
or a kinase activity, and was shown to block myeloid differentiation (Peterson et al., 2005; 
Fujimoto et al., 2007). Furthermore, CDK6 can also induce the transcription of VEGF, therefore 
promoting angiogenesis (Kollmann et al., 2013). Additionally, these regulators have been 
reported to have key roles in other fundamental processes. In hPSCs, the cyclin D-CDK4/6 
complex can direct cell fate decision, and was indeed shown to phosphorylate SMAD2/3 
preventing their entry into the nucleus and the activation of target genes driving mesendoderm 
differentiation (Pauklin and Vallier, 2013). Cyclin D1 was reported to direct DNA repair by 
binding chromatin on irradiation-induced double-strand breaks and recruiting RAD51, 
therefore promoting homologous recombination (Jirawatnotai et al., 2011). Cyclin B1-CDK1 
was instead reported to localise to the matrix of mitochondria and to phosphorylate various 
mitochondrial proteins, including components of the respiratory chain, leading to an increased 
mitochondrial respiration. This was hypothesised to allow the cell to sense and respond to the 
increased energy demand upon G2/M transition (Wang et al., 2014b). Finally, Cyclin E/A-
CDK2 complexes play a major role in tumorigenesis, by phosphorylating MYC and allowing it 
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to suppress RAS-induced senescence upon damage, thus promoting tumour formation 
(Hydbring et al., 2010). 
These are just a few examples of the non-canonical functions of cyclins and CDKs that 
have emerged over recent years, including transcription, DNA damage repair, metabolism, 
immune response, cell fate decision and differentiation (Hydbring et al., 2016). Ultimately, this 
represents a tight link between essential cellular mechanisms and cell cycle progression, and 
adds an additional layer of control to these processes. Indeed, cyclins and CDKs have emerged 
not only as regulators of cell cycle progression, but also as part of multiple and complex 
regulatory mechanisms.  
 
1.8.3 Cell cycle and haematopoiesis 
 
The earliest stages of embryonic development are characterised by short cell cycle, 
limited G1 and G2 phases and quick cell division, a feature observed also in their in vitro 
pluripotent stem cell counterpart. Studies in murine embryos and in mouse and human 
pluripotent stem cells indicate that once cells start to commit during gastrulation, they acquire 
a longer cell cycle, most notably indicated by an elongated G1 phase, and their proliferation rate 
decreases. This remodelling of the cell cycle profile has been linked to the exit from 
pluripotency, with the G1 phase representing a time window during which most of the cell fate 
decision is undertaken (Pauklin et al., 2016; Boward et al., 2016).  
Several genetic studies using mouse models have contributed over the years to shed light 
on the role of distinct cell cycle regulators during development, and importantly highlighted 
the importance of cyclins and CDKs during haematopoiesis. Remarkably, many of the 
aforementioned factors possess considerable functional redundancy, as shown by the modest 
effects observed when individual regulators are disrupted. Indeed, lack of either of the cyclin D 
members is associated only with minimal haematopoietic defects during development, the 
major impact observed with cyclin D3 affecting T lymphocyte production (Sicinska et al., 2003). 
Mutations in cyclin D2 and D3 appear to be more relevant in the adult, as shown by studies 
57 
associating these genes with an increased incidence of lymphoma (Fantl et al., 1995; Metcalf et 
al., 2010). However, the most striking effect is observed in mice deficient in all the three D 
cyclins, which die during late embryogenesis due to heart abnormalities and severe 
haematopoietic defects, characterised by significant reduction in the number of peripheral red 
blood cells. Importantly, these mice show a strong reduction in the numbers of HSPCs found 
in their foetal liver, and these fewer cells appear to be enriched in the G1 phase of the cell cycle 
and unable to provide even short-term reconstitution upon transplantation (Kozar et al., 2004). 
Similarly, individual loss of CDK4 and CDK6 produces viable embryos, and only CDK6 is 
associated with slight haematopoietic impairment. However, CDK4/6 double knockout mice 
are characterised by late embryonic lethality associated with severe anaemia and defects in foetal 
haematopoiesis, phenotypically very similar to the lack of cyclin D1/D2/D3 (Malumbres et al., 
2004). As expected, this phenotype is also confirmed by the triple knockout of all the three 
interphase kinases CDK4/6/2. Surprisingly, the severe haematopoietic impairment causing 
embryonic lethality also indicates that the cell cycle is able to progress and support proliferation 
and morphogenesis at least until this late stage, when the lethal haematopoietic phenotype 
becomes evident. This suggests that the remaining CDK1 alone is able to bind interphase cyclins 
and thus support the whole cell cycle in the absence of CDK4, CDK6 and CDK2, at least for 
early development (Santamaría et al., 2007a). This is confirmed by experiments showing that 
instead mice devoid of CDK1 fail to complete more than few divisions and die very early at the 
blastocyst stage (Diril et al., 2012). Overall this suggests that CDK1 is the principal regulator of 
the cell cycle, essential for its progression, and suggests that the remaining regulators, during 
development and possibly in the adult, might be more important for an accurate fine-tuning of 
this regulation and a balanced cell cycle progression, in addition to cell cycle independent, cell 
type-specific functions that would explain the haematopoietic phenotypes observed. 
As previously mentioned, adult HSCs are mostly quiescent and reside in the G0 phase, 
albeit ready for a rapid re-entry into the cell-cycle to respond to haematopoietic demand. This 
state is thought to be necessary for HSCs to persist for a lifetime, carefully balancing quiescence, 
proliferation and commitment towards differentiation in a tightly regulated manner. This 
ensures blood homeostasis while avoiding HSCs depletion and the accumulation of DNA 
damage. The specialised adult bone marrow niche is responsible for the maintenance of 
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quiescence, which is believed to contribute to HSC longevity and preserve their function at least 
in part by minimising stresses derived by DNA replication and cellular metabolism (Eliasson 
and Jönsson, 2010). Almost all the foetal liver HSCs (FL-HSCs) are actively cycling, possibly to 
expand the stem cell pool and at the same time satisfy blood demand during foetal development, 
and only later in the foetal liver and more prominently after seeding the bone marrow (BM-
HSCs), they gradually acquire the quiescent phenotype (Bowie et al., 2006). It is currently 
unclear if the acquisition of quiescence is necessary to complete their maturation towards an 
adult phenotype. Remarkably, both for FL- and BM-HSCs, only the fraction of cells found in 
G0/G1 is able to engraft and repopulate a host upon transplant, while cells in S/G2/M are 
temporarily devoid of this property. However, upon completing the cell cycle and reaching G1, 
these cells reacquire engraftment ability (Bowie et al., 2006). A similar finding was obtained in 
human, using cord blood HSCs, although in this case cells were maintained ex vivo for 5 days 
before transplant, which might affect their self-renewal ability (Glimm et al., 2000). 
Nevertheless, these studies delineate an important link between cell cycle state and HSC 
regenerative potential. 
Importantly, the exit from quiescence is a tightly regulated process. In this respect, long-
term (LT-) and short-term (ST-) HSCs show different division kinetics which depend on their 
cell cycle machinery. Despite both equally residing in quiescence, ST-HSCs show immediate re-
entry into the cell cycle upon mitogenic signal, while LT-HSCs show a G0 exit delayed by 5-6 
hours. This is caused by the absence of CDK6 in LT-HSCs, which needs to be expressed before 
cell cycle entry can be engaged (Laurenti et al., 2015). Overall this possibly represents a 
safeguard control mechanism for preserving the HSC pool, on one side ensuring that LT-HSCs 
only exit G0 upon sustained signals, on the other maintaining a population of ST-HSCs already 





As delineated in the previous sections, haematopoietic stem cells are of fundamental 
importance for the treatment of a variety of life-threatening diseases. However, their scarce 
availability constitutes a major obstacle, and a number of approaches have been deployed for 
their production in vitro, efforts which still remain unsuccessful. For that, understanding key 
molecular mechanisms driving their generation during development is essential. However, 
despite substantial progress that has been made over the years in this direction, our knowledge 
still remains uncomplete.  
The aim of this dissertation is to contribute to this knowledge by gaining insights into the 
fundamental mechanisms driving the onset of early haematopoiesis and that in vivo lead to the 
specification and emergence of the first haematopoietic stem cell. Towards this end, the 
objective of this study is to answer the following questions: 
 How does the endothelial-to-haematopoietic transition proceeds and what are the 
dynamics between the cell types involved? 
 What are the molecular mechanisms still unknown but fundamental for this 
transition? 
 What is the relationship between the cell cycle state and haematopoietic 
specification, and can we modulate key cell cycle regulators in order to control the 
generation and maturation of haematopoietic cells in vitro? 































2 OPTIMISATION AND CHARACTERISATION OF A 





Understanding the molecular mechanisms controlling specification and generation of 
HSPCs during early human development is challenging for obvious technical and ethical 
reasons. Indeed, developmental processes like the onset of the foetal definitive haematopoietic 
wave taking place in the yolk sac and the AGM are not easily accessible in vivo in human. Thus, 
the development of an in vitro model for HSPC production would address this major challenge. 
Human pluripotent stem cells (hPSCs) represent an advantageous platform to achieve this 
objective.  Indeed, hPSCs provide a stable and unlimited source of cells, avoiding the effects of 
the genetic diversity of primary cells which often complicate the interpretation of molecular 
mechanisms. Furthermore, differentiation of hPSCs offers an unprecedented opportunity to 
study mechanisms controlling natural paths of development in vitro. Consequently, I decided 
to take advantage of a recently published protocol for differentiating hPSCs into HPCs. This 
method recapitulates the early stages of human development for the production of progenitors 
showing characteristics of definitive haematopoiesis (Kennedy et al., 2012; Sturgeon et al., 
2014). This chapter describes the optimisation of this protocol and the characterisation of the 
resulting haematopoietic cells. 
 
2.2 Establishment and optimization of the first stages of 
differentiation 
 
The first step of this protocol consists in differentiating hPSCs as embryoid bodies (EB) 
in the presence of a cocktail of growth factors and small molecules inducing mesoderm 
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patterning and directing endothelial and haematopoietic specification, thus following 
developmental events taking place in the early embryo (Figure 2.1).  
 
Figure 2.1 Schematic of the differentiation system. In this model, during the first stage of differentiation 
EBs are directed for 9 days with a combination of growth factors and small molecules. 
 
More specifically, this approach aims at generating a mixed population of progenitors 
after 8 to 10 days characterized by the expression of the CD34 and CD43 surface markers. At 
this stage CD43 marks a more primitive population mainly capable of erythroid potential, while 
CD34+/CD43- cells represent instead progenitors of definitive foetal haematopoiesis (Kennedy 
et al., 2012). Importantly, an early stimulation of WNT signalling is able to enrich for these 
definitive progenitors (Sturgeon et al., 2014).  
In order to maximise the generation of this population, my first step was the 
optimisation of the mesoderm stage. As previously discussed (1.7), a correct recapitulation of 
the earlier stages of development is critical, especially for what concerns the induction and 
subsequent patterning of the specific mesoderm subtype capable of further differentiating 
towards an endothelial and then a haematopoietic fate. For this, I focused on modulating BMP4 
and FGF2 signalling pathways during the earliest days of differentiation, with the aim of 
achieving the highest number of CD34+/CD43- cells before further characterisation. 
Specifically, I first tested different concentrations of BMP4 during mesoderm specification, 
corresponding to the first 3 days of the differentiation protocol. This was initially done in the 
presence of low concentrations of FGF2 (2 ng/ml) and the small molecule CHIR99021, inhibitor 
of GSK3 and thus indirect activator of the WNT canonical pathway (applied as shown in Figure 
2.1).   
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The subsequent differentiation was then performed using concentrations of growth 
factors as previously described (Sturgeon et al., 2014), carried on until day 9 (D9) and then 
tested by flow cytometry for the expression of the surface markers CD34 and CD43. These 
experiments revealed that different concentrations of BMP4 caused only a minor change in the 
expression of CD34, but an important effect on the number of CD43+ cells. Based on this result, 
I determined that the best dose of BMP4 for mesoderm induction and patterning was 10 ng/ml 
(Figure 2.2).  
 
Figure 2.2 Optimisation of BMP4 concentration during mesoderm specification. Differentiation was 
performed using low levels of FGF2 (2 ng/ml) and testing different concentrations of BMP4 during mesoderm 
induction and patterning. It was carried on until D9 following the standard protocol, and expression of CD34 
and CD43 was assessed by flow cytometry. n=1 experiment. 
 
Subsequently, I repeated these experiments using the selected dose of BMP4, and testing 
for different concentrations of FGF2. In this case, the number of CD34+ cells was affected, with 
only small changes for CD43 (Figure 2.3). 
 
Figure 2.3 Optimisation of FGF2 concentration during mesoderm specification. Differentiation was 
performed using the best concentration of BMP4 as determined from the previous experiment (10 ng/ml) and 
testing different concentrations of FGF2 during mesoderm induction and patterning. It was carried on until D9 
following the standard protocol, and expression of CD34 and CD43 was assessed by flow cytometry. Graphs 
are representative of technical duplicates from n=1 experiment. 
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Ultimately, this approach allowed me to select 10 ng/ml of BMP4 and 5 ng/ml of FGF2 
as the best combination to achieve induction and patterning of the correct mesoderm subtype 
competent for the generation of CD34+/CD43- cells.  
As briefly mentioned, the CD43 compartment at this early stage represents a population 
of primitive embryonic progenitors mostly capable of differentiation into erythroid cells. On 
the other hand, the CD34+/CD43- population is not supposed to have haematopoietic colony 
forming capability, but instead to represent progenitors with the potential of further 
differentiating towards a definitive foetal phenotype upon co-culture on OP9 mouse bone 
marrow stromal cells (Kennedy et al., 2012; Sturgeon et al., 2014). To test this hypothesis, hPSCs 
were induced to differentiate into mesoderm using the selected conditions and then further 
differentiated until D9. The resulting cells were then sorted based on their expression of CD34 
and CD43 into three populations (CD34+/CD43-, CD34-/CD43+, CD34+/CD43+) and then 
further differentiated in a colony-forming unit (CFU) assay, in order to assess their potential 
for differentiation towards the erythroid and myeloid lineages (Figure 2.4). The assay confirmed 
that at this stage only CD43+ cells were capable of producing haematopoietic colonies. More 
specifically, CD34-/CD43+ cells were able to give almost exclusively erythroid colonies, while 
CD34+/CD43+ cells contained a much lower number of colony-forming cells, although of 
mixed identity. Most importantly, CD34+/CD43- cells were confirmed to not be able to 
generate any colonies at this stage of differentiation.  
 
Figure 2.4 Maturation potential of D9 cells in a CFU assay. Cells were differentiated until D9 and distinct 
populations were FACS-sorted based on their expression of CD34 and CD43 surface markers. For each sorted 
population, 1,500 cells were used for a CFU assay to confirm their maturation potential. n=1 experiment. 
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During the establishment and optimisation of these first steps of differentiation, an 
updated version of the protocol became available (Ditadi et al., 2015). The first stage of this 
revised protocol had undergone only minor changes, still relying on an EB system for 
mesoderm induction and patterning, and for endothelial specification. However, a major 
improvement was included in the second stage by avoiding the use of feeder cells. Indeed, cells 
sorted as CD34+/CD43- were directly plated on Matrigel-coated plates and cultured as a 2D 
monolayer to undergo an endothelial-to-haematopoietic transition similar to events taking 
place in vivo during foetal development. This improved approach had the important and 
attractive feature of being entirely feeder-free and relying on the use of well-defined culture 
conditions, therefore eliminating the requirement for OP9 mouse bone marrow stromal cells. 
For these reasons, I decided to continue with this revised version of the differentiation protocol.  
As briefly mentioned, in addition to this important improvement, few alterations also 
appeared to have been made to the first stage of the protocol, specifically a reduction in the 
number of cytokines applied after D5, a slight change in the timing of their administration and 
an anticipation to D8  for the sorting of CD34+/CD43- cells (Figure 2.5). 
 
Figure 2.5 Comparison between the first stage of the two protocols.  Here a schematic of the first stage of 
differentiation is shown, comparing the two versions.  
 
68 
By comparing the two methods using mesoderm induction and patterning conditions 
as previously selected, I was able to show that the revised protocol generates a higher number 
of CD34+/CD43- cells at D8, one day earlier compared to the previous version (Figure 2.6). 
Therefore, I decided to use the new version of the protocol for the production of the 
intermediate CD34+/CD43- population and to test the second stage of differentiation 
modelling the endothelial-to-haematopoietic transition. 
 
Figure 2.6 Comparison between the two protocols for the generation of CD34+/CD43- cells. 
Differentiation was performed using the two systems described, and assessing the expression of CD34 and 
CD43 by flow cytometry between D7 and D9 of differentiation. This approach allowed me to select the best 
protocol and determine the trend of expression for the markers analysed. Graphs are representative of 
technical duplicates from n=1 experiment. 
 
2.3 Characterisation of the endothelial-to-haematopoietic 
transition stage 
 
In order to use this in vitro model to uncover mechanisms controlling early 
haematopoiesis, after a first optimisation of the system my efforts were then focused on 
characterising the generation of haematopoietic progenitor cells (HPCs). Ultimately, my aim 
was to identify the exact time window during which HPCs are first generated from haemogenic 
endothelial cells (HECs) in vitro.   
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For this, CD34+/CD43- cells sorted at D8 were re-aggregated overnight into small 
clumps and seeded the day after onto Matrigel-coated plates, marking the first day of 
endothelial-to-haematopoietic transition culture (EHT D1). This allowed for the cells to attach 
and grow to form a layer of endothelial cells at EHT D3, from which during the next 2 days by 
EHT D5 clusters of round cells were produced, resembling intra-aortic haematopoietic clusters 
(IAHCs) generated in vivo (Figure 2.7). These clusters appeared to keep attachment to the 
underlying endothelium, and on the subsequent days they showed an increase in their size and 
most importantly the generation of new cells which started to be released as single cells floating 
in the culture medium, with their numbers increasing dramatically on the following days.  
This process appeared to morphologically recapitulate developmental events taking 
place during EHT in the foetal yolk sac and AGM region, corresponding to the release from the 
haemogenic endothelium (HE) of the first HSPCs which then migrate to the foetal liver for 
further maturation and expansion. 
 
Figure 2.7 Culture system for in vitro modelling of EHT. The protocol allows modeling the generation of 
IAHC from the HE, which produces and releases cells in the culture media. Scale bar is 400 μm. 
 
The endothelial identity of cells used for this second stage of differentiation was 
confirmed by the co-expression of CDH5. Indeed, this endothelial marker appeared to be 
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expressed on the majority of the CD34+ cells sorted at D8 (Figure 2.8A). Importantly, during 
the EHT culture the number of cells expressing this marker rapidly decreased, concomitant 
with an increase in the number of cells expressing the pan-haematopoietic marker CD43, first 
surface marker reported to appear on HSPCs generated both in vitro and in vivo (Vodyanik et 
al., 2006; Ivanovs et al., 2014a). The inverse correlation for the expression of these markers 
illustrated the transition from an endothelial to a haematopoietic cell identity (Figure 2.8B). 
 
 
Figure 2.8 Characterisation of EHT by flow cytometry. (A) CD34+/CD43- cells were sorted at D8, marking 
the initial day of EHT culture (EHT D0).  Most of these cells also co-expressed the endothelial marker CDH5. (B) 
On the subsequent days, EHT was characterised by the acquisition of CD43 marking the first haematopoietic 
cells generated, concomitant with the loss of CDH5. Results in (A) and (B) represent n=3 independent 
experiments, with error bars ±SEM. (C) The first haematopoietic cells generated during EHT were 
CD34+/CD43+. Subsequently, most of these cells lost the expression of CD34. n=1 experiment. 
 
This transition was also evident by looking at the expression of key marker genes by 
quantitative polymerase chain reaction (qPCR; Figure 2.9). The expression of endothelial 
markers, such as VWF, PECAM1 and CDH5, showed an inverse progression over time 
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compared to haematopoietic differentiation markers, such as SPI1, GATA1 and KLF1. It was 
also interesting to observe the trend of expression for key markers and transcription factors 
usually associated with HSC specification and function, like RUNX1, MEIS1, GATA2, GFI1 and 
MYB. Indeed, all these markers appeared to show a peak of expression at EHT D3, 
corresponding with the first morphological appearance of the haematopoietic clusters in 
culture. The observation that these key HSC factors showed the highest expression at EHT D3 
and decreased afterwards, along with the fact that differentiation markers appeared to increase 
over time, suggested that EHT in these culture conditions was a very transitory process and that 
once generated, HPCs were either unstable and directly proceeded towards more differentiated 
cell types, or that they quickly became outnumbered by more mature cell types.  
 
 
Figure 2.9 Characterisation of gene expression during EHT. The expression of key haematopoietic and 
endothelial genes was measured during EHT by qPCR. CD34+ peripheral blood mononuclear cells (PBMCs) 
from primary samples are shown as control. Results for EHT cultures represent n=3 independent experiments, 
with error bars ±SEM. Results for PBMCs represent n=2 independent samples, with error bars ±SEM. 
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In order to confirm if this culture system was able to generate functional HPCs capable 
of maturation into different blood cell types, cells generated during EHT were tested for their 
capability to terminally differentiate. For this, cells were collected at EHT D5 and used for a 
CFU assay. By the end of the assay, I could observe the production of different colonies of 
erythroid and myeloid lineages, confirming that the in vitro generated HPCs were functional 
and able to further differentiate. Most importantly I could also confirm the presence of colonies 
of mixed phenotype, representative of multipotent haematopoietic progenitors (Figure 
2.10A,B). These terminally differentiated cells were collected and further analysed by qPCR for 
the expression of haemoglobin genes. Using this approach, I was able to show that the resulting 
red cells expressed the foetal γ globin encoded by the HBG genes, with lower levels of expression 
of the embryonic isoform ε globin, encoded by HBE1 (Figure 2.10C). This result was consistent 
with previous studies showing a similar pattern occurring during development, when the main 
site of haematopoiesis is shifting from the AGM region towards the foetal liver and the first 
haemoglobin isoform switch is taking place with the γ globin becoming predominant  
(Sankaran and Orkin, 2013). This suggested that HPCs generated in these culture conditions 
recapitulated the onset of foetal definitive haematopoiesis, as opposed to embryonic primitive 
haematopoiesis. At the same time, lack of expression of the adult isoform β globin encoded by 
HBB was not surprising, considering that in vivo this second switch from γ to β globin only 
happens shortly after birth. 
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Figure 2.10 Terminal differentiation of HPCs generated in vitro. (A, B) Cells at EHT D5 were collected and 
used for a CFU assay. Progenitors generated in these culture conditions were capable of terminal maturation 
to cells of different blood lineages. (C) qPCR data showed that the main β-like globin isoform expressed by red 
cells generated at the end of the CFU assay was the foetal γ globin. Results represent n=3 independent 




In this chapter, I described the optimisation and characterisation of a model system for 
the recapitulation of early developmental events taking place during foetal haematopoiesis and 
leading to the generation of HSPCs from the haemogenic endothelium. My strategy was based 
on the use of hPSCs as an unlimited source of cells to be used for this in vitro differentiation, 
with the aim of uncovering fundamental molecular mechanisms driving the onset of definitive 
haematopoiesis in human, thus overcoming the difficulty of studying this process in vivo due 
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to limited accessibility. My first efforts were directed towards the optimization of the culture 
conditions used to generate the intermediate population of CD34+/CD43- cells. Indeed, the 
exact molecular requirements for the induction of pluripotent stem cells to differentiate show 
variation across distinct cell lines (Cahan and Daley, 2013). This is caused by genetic and 
epigenetic heterogeneity, which causes cell line variability in their response to distinct signalling 
pathways, ultimately resulting in lineage biases. For this reason, I decided to focus on the earliest 
days of the protocol corresponding to early germ layer development. This is certainly a key step, 
given that the specification of the correct germ layer is essential for the generation of any specific 
cell type in vitro. Importantly, enrichment for cells representing primitive or definitive 
haematopoiesis was shown to be mediated by signalling pathways at the mesoderm stage 
(Slukvin, 2013). Indeed, the two haematopoietic waves appear to derive from distinct mesoderm 
subtypes, and modulation of WNT signalling is able to control this early cell fate decision 
(Sturgeon et al., 2014). Of note, a similar role was previously shown for the activation or 
inhibition of the Activin/NODAL/TGFβ pathway at the same stage, leading to an enrichment 
of primitive or definitive haematopoiesis, respectively (Kennedy et al., 2012). Thus, one 
possibility is that redundant mechanisms might control similar differentiation outcomes. 
Alternatively, a crosstalk between the two signalling pathways might be in place for the 
regulation of downstream mechanisms directing differentiation. Therefore, a combined 
modulation of the two signalling could possibly allow for a more accurate control over this early 
cell fate decision event. For my experiments I performed the activation of the WNT canonical 
pathway and optimised BMP and FGF signalling during mesoderm induction and patterning. 
With this approach, I was able to increase the efficiency of generation of CD34+/CD43- cells.  
I confirmed this population to represent endothelial cells able to transition to the 
haematopoietic fate and generate cells resembling the IAHCs produced in vivo during 
development. Importantly, I showed that these cells have the ability to further differentiate in a 
CFU assay, and I confirmed that the resulting red cells mainly express foetal γ-globin, expressed 
during the definitive haematopoietic wave. This is also in agreement with previous findings 
showing this model to possess the potential to generate T lymphocytes (Ditadi et al., 2015), 
suggested to be a hallmark of definitive haematopoiesis and initially produced during 
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development from the yolk sac and the AGM region (Böiers et al., 2013; McGrath et al., 2015). 
In agreement with this, the current protocol was recently suggested to produce cells which are 
very close to an HSC state. Indeed, haemogenic endothelial cells produced with this 
differentiation system, but not other types of endothelium such as human umbilical vein 
endothelial cells, acquired multilineage engraftment potential when induced to ectopically 
overexpress seven specific transcription factors important for HSC specification and function 
(Sugimura et al., 2017). Furthermore, the acquisition of reconstitution potential with this 
approach was not successful when cells were induced prior to EHT D3, suggesting that the onset 
of EHT is essential for the establishment of the correct molecular landscape necessary for the 
induction of an HSC-like state. Importantly, this is in agreement with my gene expression data 
suggesting that the peak of expression of factors considered to be fundamental for HSPC 
specification takes place at EHT D3. Potentially, this time point represents the onset of 
transcriptional programmes leading to the first HPCs in vitro, and the stage when the induction 
to an HSC-like state becomes possible. Of note, the morphological appearance of 
haematopoietic clusters takes place between EHT D3 and EHT D5. Based on these observations, 
I hypothesised this specific stage to constitute a short and transitory time window during which 










3 ANALYSIS OF IN VITRO HUMAN 





In the previous chapter, I have shown that the generation of HPCs in vitro involved 
endothelial cells transitioning toward a haematopoietic cell identity, similarly to the EHT 
happening in vivo. This is likely to be a progressive and gradual transition rather than a sudden 
single step leap, composed of continuous consecutive states. Some cells will be engaged in EHT, 
and some others will have already completed the transition and potentially will be free to further 
differentiate. This also implies that the EHT culture is a very heterogeneous system, with 
different cell types and states coexisting and often sharing similar characteristics, especially cell 
surface markers. Thus, isolation of different cell states by conventional cell sorting strategies 
could be difficult if not impossible, rendering the study of molecular mechanisms directing the 
transition very challenging. To overcome these limitations, I decided to take advantage of single 
cell RNA sequencing (scRNAseq), which allows the study of the transcriptional landscape of 
individual cells. As anticipated in the previous chapter, there is a specific time window during 
which clusters similar to the IAHCs are produced in vitro and when the HSPCs transcriptional 
programme appears to be activated. Therefore, cells involved in the transition at this particular 





3.2 Identification of distinct cell types involved in the 
endothelial-to-haematopoietic transition 
 
For the experiment, hPSCs were differentiated as described in Chapter 2.3, and cells were 
collected at EHT D3 and EHT D5 for scRNAseq. The bioinformatic analyses of the 
transcriptional data reported in this dissertation were performed with the help of Dr 
Emmanouil I. Athanasiadis from Dr Ana Cvejic’s group. 
Briefly, based on transcriptional data and after removal of cells that did not pass quality 
control, we performed cell clustering in the 3D t-distributed Stochastic Neighbor Embedding 
(tSNE) space. With this approach we originally identified multiple clusters of cells, and upon 
calculation of the average expression level of the top 20 marker genes per cluster, we were able 
to merge highly correlated clusters based on transcriptional similarity, ending up with the final 
identification of 4 distinct populations of cells in our samples (Figure 3.1A).  
 
Figure 3.1 Cell clustering in the 3D tSNE space. (A) Based on transcriptional identity, we were able to identify 
4 clusters in the tSNE space. (B) The top 10 marker genes are shown in the heatmap for each cluster. For this 
analysis, EHT D3 and EHT D5 samples were combined. 
 
We then calculated the marker genes of the resulting clusters (Figure 3.1B) and 
monitored the expression of known lineage genes to assign cell identity. Based on these results, 
one group of cells was labelled as endothelial cells, as it was shown to express endothelial 
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markers including CDH5, KDR, PECAM1, ECSCR and ENG (Figure 3.2). It was interesting to 
note that this cluster also expressed low levels of CD43, along with intermediate or low levels of 
key transcription factors involved in HSC specification, such as RUNX1, GATA2, TAL1 and 
SOX18 (Figure 3.3). Additionally, at least part of this cluster also expressed genes like SOX17, 
known to mark HECs surrounding newly generated IAHCs (Lizama et al., 2015), or HOXA7, 
HOXA9 and HOXA10, suggested to characterize the onset of definitive haematopoiesis and the 
generation of the first HSCs in vivo (Ng et al., 2016; Dou et al., 2016). These observations were 
therefore consistent with an HE profile.  
 
Figure 3.2 Endothelial and mesenchymal lineage markers. Based on the expression of CDH5, KDR, PECAM1, 
ECSCR and ENG, cluster 1 was labelled as endothelial cells. Importantly, this cluster also contained genes 
marking the HE like SOX17, or genes important for specification of definitive HSPCs, like SOX18, HOXA7, HOXA9, 
HOXA10. Based on the expression of genes such as CDH2, CDH11, COL1A1, KRT8 and TAGLN, cluster 2 instead 
was labelled as mesenchymal cells. Expression of key lineage markers refers to EHT D3 and EHT D5 data 
combined, and are shown as (A) tSNE plots and (B) violin plots. Numbers on the x axis in violin plots (1 - 4) 




Figure 3.3 HSPC and erythroid lineage markers. Cluster 3 and 4 both appeared to express haematopoietic 
markers such as CD43, RUNX1, MYB, GATA2, GFI1 and TAL1. Cluster 3 appeared to be particularly enriched in 
erythroid genes, such as GYPA, ALAS2, GATA1, KLF1 and several haemoglobin isoforms, while cluster 4 showed 
a much lower expression for these genes, while also showing low expression of other blood lineage genes 
(Figure 3.4). For this and for the lack of mature blood cell morphologies (Figure 3.5), cluster 3 was labelled as 
erythroid progenitors, while cluster 4 as HPCs. Lower levels of key haematopoietic markers, co-expressed with 
endothelial genes, were also found on cluster 1, consistent with an HE identity. Expression of key lineage 
markers refers to EHT D3 and EHT D5 data combined, and are shown as (A) tSNE plots and (B) violin plots. 
Numbers on the x axis in violin plots (1 - 4) correspond to cluster numbers as in Figure 3.1. 
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Two clusters appeared instead to be positive for haematopoietic markers such as 
RUNX1, CD43 and TAL1 (Figure 3.3). Cluster 3 was particularly enriched for factors known to 
characterise the erythroid lineage, like GYPA, ALAS2, GATA1, KLF1 and different haemoglobin 
isoforms. However, the May–Grünwald-Giemsa stain I performed with samples from EHT D5 
showed the absence of cells with clear erythroid or other mature blood cell morphologies 
(Figure 3.5). Instead, the histological morphology was similar and consistent with a previous 
study where the same staining was performed on EHT samples from mouse E11.5 AGM 
(Taoudi et al., 2005). Prompted by these observations, I hypothesised these cells to represent 
progenitors committed to the erythroid lineage but not yet showing the typical differentiated 
morphology or high levels of lineage genes. Cluster 4 on the other hand was the more interesting 
of the two haematopoietic groups of cells. Indeed, it expressed low levels of myeloid markers 
such as SPI1 and CD33 (Figure 3.4), but it was also weakly positive for erythroid factors such as 
GATA1, KLF1, and even very low levels of haemoglobins. Small portions of this cluster showed 
expression of megakaryocyte markers as ITGA2B and GP1BA, or lymphoid genes as CD3 and 
RUNX3 at very low levels. Most importantly, the cluster mainly expressed transcription factors 
involved in HSPC specification and function, namely RUNX1, MYB, GFI1 and GATA2 (Figure 
3.3). All these observations led me to hypothesise that this cluster might represent the first 
population of HPCs, possibly multipotent progenitors with the ability to differentiate towards 
different blood cell types, as suggested by the heterogeneous gene expression profile. 
Finally, a fourth group of cells did not appear to express high levels of either endothelial 
or haematopoietic markers. Instead, it expressed factors involved in processes like wound 
healing and muscle tissue morphogenesis, and it was characterized by genes like CDH2, CDH11, 
COL1A1, KRT8 and TAGLN (Figure 3.2). Thus, I labelled the cluster as mesenchymal cells. 
Importantly, the identification of this population highlighted the power of the analysis, which 







Figure 3.4 Myeloid, megakaryocytic and lymphoid lineage markers. Cluster 4 was shown to have low 
expression levels for myeloid genes like SPI1 or CD33, megakaryocytic markers like ITGA2B and GP1BA, or very 
low levels of lymphoid genes like CD3D and RUNX3. Combined with low levels of erythroid markers and with 
the higher expression of genes involved in HSPC specification (Figure 3.3), this suggested the cluster to 
represent multipotent HPCs. Expression of key lineage markers refers to EHT D3 and EHT D5 data combined, 
and are shown as (A) tSNE plots and (B) violin plots. Numbers on the x axis in violin plots (1 - 4) correspond to 
cluster numbers as in Figure 3.1. 
 
 
Figure 3.5 Histological staining of cells at EHT D5. Cells were collected at EHT D5, prepared on microscopy 
slides by cytospin centrifugation and stained with May–Grünwald-Giemsa method. The assay revealed the 
absence of obvious morphologies indicating the presence of terminally differentiated blood cells in culture, 
but consistency with previous studies of mouse HE during EHT from E11.5 AGM. Scale bar is 15 μm. 
 
 
To confirm these hypotheses, I used the scRNAseq dataset to identify surface markers 
with the aim of designing a simple but effective sorting strategy which would allow me to isolate 
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or enrich for distinct populations and therefore confirm the assigned identities in a functional 
experiment. This was of fundamental importance for the subsequent steps of my investigation, 
and it was indeed crucial for the correct interpretation of molecular mechanisms uncovered by 
this analysis. My primary focus was the isolation of cluster 4, which I hypothesised to be the 
first population of multipotent HPCs generated in vitro. Using this approach, I ultimately 
selected the surface markers CDH5, CD43 and CD44 (Figure 3.6).  
 
Figure 3.6 Markers used for the isolation of distinct populations. Based on scRNAseq data, CDH5, CD43 
and CD44 were chosen to design a sorting strategy for the isolation of the clusters identified.  
 
CDH5 was mainly expressed in cluster 1, which I labelled as endothelial cells. 
Importantly, it appeared to also be very weakly expressed on portions of cluster 3 and 4. As 
already mentioned, CD43 is a pan-haematopoietic marker and it was shown to be expressed on 
cluster 3 and 4, which based on the markers shown above I hypothesised to be erythroid 
progenitors and multipotent HPCs, respectively. CD44 was instead expressed prevalently on 
cluster 2, previously labelled as mesenchymal cells, as well as on cluster 4 and, at lower levels, 
on cluster 1 (Figure 3.6). Interestingly, CD44 was previously shown to be expressed on a 
plethora of cell types in vivo, but most importantly it was suggested to be expressed on IAHCs 
emerging during EHT both in human and mouse (Watt et al., 2000; Ohata et al., 2009). 
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Figure 3.7 Sorting and functional validation of distinct clusters. (A) Using this strategy, six populations 
were FACS-sorted at EHT D5 for further functional validation. (B) The six sorted populations corresponded to 
distinct fractions of cells in the tSNE plot, based on the expression of the selected markers. (C) After isolation, 
1,000 cells per population were tested in a CFU assay, and the colonies obtained were scored based on their 
morphology and plotted individually (left) or based on their erythroid or myeloid identity (right). The 
percentage of multilineage CFU-GEMM colonies on the total number of colonies obtained is also shown. 
Results represent n=2 independent experiments, with error bars ±SEM. 
 
Using this combination of surface markers, I was able to sort at EHT D5 six distinct 
populations, which I then tested in a CFU assay in order to assess their differentiation potential 
(Figure 3.7) Importantly, CDH5-/CD44+/CD43- (P1) and CDH5+/CD44+/CD43- (P4) cells, 
corresponding to populations previously labelled as mesenchymal and endothelial cells 
respectively, did not show significant levels of blood colonies, confirming their lack of 
haematopoietic potential at this stage. On the other hand, CDH5-/CD44-/CD43+ (P2) and 
CDH5+/CD44-/CD43+ (P5) cells were exclusively able to generate colonies representative of 
the erythroid lineage, and more specifically CDH5-/CD44-/CD43+ cells had a higher 
enrichment in the number of mature CFU-E colonies, thereby suggesting a higher level of 
commitment. Based on these results, I speculated these two populations to represent distinct 
portions of cluster 3, labelled as erythroid progenitors. Part of this cluster is indeed weakly 
positive for CDH5 in our transcriptomics data and could represent a less committed type of 
progenitor, as indicated by a different number of CFU-E generated. Finally, CDH5-
/CD44+/CD43+ (P3) and CDH5+/CD44+/CD43+ (P6) were able to generate all the different 
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types of colonies. As for cluster 3, the two populations potentially represented distinct portions 
of the same cluster 4, given that only part of this cluster was shown to be positive in the 
transcriptomic analysis for CDH5, which once again seemed to mark the transition from an 
early to a late progenitor state. These two populations not only had the ability to differentiate 
into all the different types of colonies, but they also showed a limited number of CFU-E 
colonies, suggesting a lower degree of commitment. These colonies are indeed derived from 
mature erythroid progenitors which are also very proliferative and therefore usually 
predominant even in unsorted samples. Most importantly, these two populations showed an 
important enrichment in the amount of the CFU-GEMM type of colony, representative of 
multipotent progenitors and not produced by the remaining 4 populations sorted. Specifically, 
19.74% and 14.04% of all the blood colonies produced in the assay by CDH5-/CD44+/CD43+ 
and CDH5+/CD44+/CD43+ cells, respectively, were CFU-GEMM, against only a 3.32% 
generated in the unsorted sample. This confirmed that the two populations were indeed 
enriched in multipotent progenitors as hypothesised based on transcriptomics data, and 
highlighted the effectiveness of the sorting strategy. 
All these findings together confirmed the cluster identities previously assigned based on 
gene expression. Cluster 1 and 2 are non-haematopoietic groups of cells likely to represent 
endothelial and mesenchymal cells, respectively, based on their gene expression profiles. The 
remaining clusters are haematopoietic populations. Specifically, cluster 3 contains progenitors 
that can only produce erythroid colonies, while cluster 4 is able to generate multiple types of 
erythroid and myeloid colonies and most importantly is highly enriched with multilineage 
potential, and thereby likely represents multipotent HPCs. Additionally, my data suggested the 
possibility of using CDH5 to mark distinct states of maturation for haematopoietic progenitors, 





3.3 Analysis of EHT progression by scRNAseq 
 
Having confirmed their identity by functional validation, it was interesting to see how the 
4 clusters progressed over time from EHT D3 to EHT D5. This time window represented the 
most likely culmination of the transition from the endothelial to haematopoietic cell fate and 
thus was chosen for the study of this developmental process. For this analysis the sequencing 
data, previously combined for the identification of the distinct populations, was now used for a 
comparison between the two time points. 
From this comparison it was evident that the major change from EHT D3 to EHT D5 
involved a reduction in the endothelial cluster and an increase in the haematopoietic 
compartment, especially for the erythroid progenitors (Figure 3.8A). The cluster of multipotent 
HPCs only showed a small increase, possibly indicating that once generated these cells have a 
low proliferation rate. Alternatively, they might represent a transitory population which quickly 
commits and is immediately replaced by new cells. It was interesting to note how the increase 
in the haematopoietic compartment at the expense of the endothelial cluster seemed to directly 
represent the EHT process and the progression from one cell type to the other. Importantly, the 
mesenchymal cluster did not appear to be affected.  
87 
 
Figure 3.8 Cluster progression during EHT. (A) Comparing the two time points, the major change appeared 
to be a reduction in the endothelial cluster and an enrichment in the haematopoietic compartment, especially 
for the erythroid progenitors. (B) In the pseudotime trajectories, it was also possible to see that the branch 
point, likely to be occupied by cells in the transition process, was less populated at EHT D5, while the 
haematopoietic branch showed cells progressing further towards the end point. Overall these trajectories gave 
a graphical representation of EHT based on transcriptional data. 
 
We were also able to use our single cell transcriptomics data to further elucidate 
mechanisms controlling EHT. For that, we generated pseudotime trajectories depicting the 
transition between different cell states using the package Monocle2 (Trapnell et al., 2014; Qiu 
et al., 2017a; Qiu et al., 2017b). In brief, the analysis took advantage of the fact that individual 
cells engaged in a progressive process are usually asynchronous for their progression along that 
process. This means that at any time distinct cells will be at slightly different stages and therefore 
form a continuum from point A to point B in that specific process, with their gene expression 
reflecting such variability.  Monocle allows to take a multitude of variable genes across the whole 
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sample into consideration and use their expression to deconstruct this asynchrony and align 
individual cells in a pseudotemporal order. With this approach, we were able to use our data to 
generate pseudotime trajectories (Figure 3.8B). Confirming our expectations, the analysis 
appeared to depict a transition from the endothelial cluster to the haematopoietic compartment 
containing both erythroid progenitors and multipotent HPCs, in agreement with the identities 
previously assigned. In addition, the analysis suggested the possibility that the mesenchymal 
cluster might also be directly derived from endothelial cells. Furthermore, a comparison 
between pseudotimes for the two time points revealed that during this time most of the cells 
that were engaged in the transition successfully completed their commitment, as shown by the 
fact that the branch point, likely to be populated by cells undergoing the transition at EHT D3, 
was  instead poorly occupied at EHT D5, when cells appeared to show higher density at the end 
points of the trajectory.  
Overall, the analysis allowed to gain important insights on the populations participating 




In this chapter, I took advantage of novel technologies for single cell transcriptomics to 
study the EHT process leading to the generation of early HPCs. This technique, combined with 
the in vitro system previously described, allowed me to define with unprecedented detail the 
transcriptional signature of cells involved in the transition. This allowed me to characterise the 
endothelial cells undergoing EHT with single cell precision, and to determine that two distinct 
populations of haematopoietic cells were present in this culture system. A first group of cells 
had an erythroid transcriptional identity and was confirmed to produce exclusively erythroid 
colonies. A second smaller fraction of cells expressed instead low levels of different lineage 
markers, but also transcription factors involved in HSPCs specification and thus resembling 
multipotent progenitors. Importantly, the latter population was functionally confirmed to 
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possess multilineage differentiation potential, and therefore to likely constitute the first example 
of multipotent progenitors generated in this system.  
The comparison of single cell transcriptomics data for two consecutive time points during 
the EHT process allowed me to study for the first time the evolution of this transition. This 
approach revealed that the number of multipotent HPCs increased only slightly during the time 
considered, an observation which might be explained by different hypotheses. One possibility 
is that, once generated, these cells have a low proliferation rate and possibly, over the 48 hours 
analysed in the study, maintain their number stable through asymmetric division, therefore 
contributing to the erythroid population. Alternatively, most of the HPCs might quickly 
commit and contribute to the erythroid cluster, while at the same time being replaced by cells 
freshly generated from the HE, with the total number of multipotent HPCs remaining almost 
constant over time, at least for the short time window taken into consideration. This would 
suggest the HPC population to be extremely transitory, characteristics perhaps exacerbated by 
culture conditions not optimised for the stabilisation of the stem/progenitor state. A third 
scenario could be represented by a synthesis of the two hypothesis. Part of the HPCs might 
indeed quickly commit and contribute to the erythroid cluster, and be replaced by new cells 
generated both as a result of HPC asymmetric cell division and of endothelial cells transitioning 
to the haematopoietic fate. Interestingly, in all these scenarios the erythroid commitment 
appears to be the dominant differentiation programme, while other fate choices are expressed 
when more permissive conditions become available, such as in a CFU assay. This might suggest 
that further optimisation of the EHT culture conditions is necessary to prevent the generated 
progenitors from rapidly committing. Indeed, the strong decrease in the number of endothelial 
cells corresponding to the increase in the erythroid cluster suggests that the intermediate HPC 
state is extremely transitory in these culture conditions. 
An additional cluster identified in the analysis was constituted by mesenchymal cells, 
previously unexpected in this in vitro system. This group was characterised by the expression 
of genes involved in smooth muscle tissue morphogenesis, wound healing and matrix 
deposition, and I originally hypothesised it to be an undesired by-product of the differentiation 
protocol, possibly caused by culture conditions which should be further optimised. Indeed, it 
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could be possible that endothelial and mesenchymal cells have a common origin from 
mesodermal precursors, and that a suboptimal differentiation fails to prevent the generation of 
mesenchymal cells. Alternatively, they might instead represent a cell type contributing and 
necessary for the formation of the correct developmental niche from which HSPCs are 
generated in vivo in the dorsal aorta and recapitulated in vitro in this model system. Indeed, 
mesenchymal cells have been previously reported to originate in the AGM prior to the HSPC 
emergence and to participate to the haematopoietic niche, possibly with a supportive role 
similar to what is observed in the bone marrow (Wang et al., 2008). It is therefore possible that 
these cells are also required for the generation of functional haematopoietic cells in vitro. 
Additionally, the generation of pseudotime trajectories, beyond providing an important 
confirmation for the EHT as a progression from an endothelial to a haematopoietic fate, 
revealed the potential developmental origin of mesenchymal cells. Indeed, the analysis 
suggested that the mesenchymal cluster might be directly derived from endothelial cells, 
potentially through an endothelial-to-mesenchymal transition (EndoMT) which was 
previously described in vivo both in development and disease (Ten Dijke et al., 2012; Chen et 
al., 2015; Good et al., 2015; Zhong et al., 2018; Man et al., 2018). This could represent a biological 
process overlapped with EHT and perhaps necessary for the emergence of IAHCs. Additionally, 
EndoMT and EHT might also represent two divergent directions originating from a common 
endothelial progenitor. As such, this might constitute a cell fate decision event, with the balance 
between the two transitions possibly controlled by similar mechanisms to determine if 
endothelial cells will undertake the haematopoietic or mesenchymal fate. Of note, our data 
showed the mesenchymal cluster to remain almost constant between the two time points. This 
could be caused by culture conditions optimised for the promotion of EHT, and it is possible 
that modulation of specific signalling pathways might change this behaviour and increase 
EndoMT. In this regards, TGFβ was reported to promote EndoMT (Wermuth et al., 2016), and 
it would be interesting to test if this signalling could also play a role in this in vitro system. 
An important result achieved with the experiments presented was the design of a simple 
and effective sorting strategy that allowed me to isolate the distinct populations and functionally 
test their blood differentiation capacity. Using this approach, I was able to corroborate the non-
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haematopoietic identity of the endothelial and mesenchymal clusters. Furthermore, I could 
confirm the restricted differentiation capability of the erythroid population and the wider 
multilineage potential of the HPC cluster. Of note, it is also possible that the HPC cluster is 
composed of multiple progenitors with different fate propensities, as previously discussed for 
the HSPC compartment in vivo (Chapter 1.2). Indeed, the multilineage potential was observed 
at the population level, and single cell functional experiments will be necessary to further test 
the differentiation capability of individual cells within the cluster. Nevertheless, the possibility 
of isolating the first population of multipotent progenitors generated in vitro based on the 
expression of the three markers CDH5, CD43 and CD44 was an important achievement, and 
paves the way to future studies specifically addressing this population. Interestingly, it was 
previously suggested that CD43 is the first surface marker to appear during the generation of 
HSPCs, both in vitro and in vivo (Vodyanik et al., 2006; Ivanovs et al., 2014a). Importantly, here 
I have shown that the co-expression of CD43 and CD44 specifically marks a population 
possessing multilineage potential. In agreement with these results, CD44 was previously 
reported to be expressed on IAHCs in the AGM region, both in human and mouse (Watt et al., 
2000; Ohata et al., 2009), and to be involved in the migration of foetal HSCs and in their homing 
to the bone marrow (Cao et al., 2016). Our data also revealed that the mesenchymal cluster, 
similarly to HPCs, express high levels of CD44. This would be in agreement with previous 
studies reporting the appearance of mesenchymal cells in the AGM and their presence at 
subsequent haematopoietic sites, including foetal liver and bone marrow, along with the 
embryonic circulation, suggesting that at least some of these cells might migrate across different 
haematopoietic sites during development (Mendes et al., 2005). Therefore, CD44 could possibly 
be involved in the migration of both HSPCs and mesenchymal cells, and allow their homing to 
common sites during haematopoietic development. Additionally, I proposed that the 
expression of CDH5 possibly marks earlier subpopulations within the two haematopoietic 
clusters. Both CDH5+ and CDH5- HPCs have similar differentiation potential, with the latter 
population possessing higher multilineage capacity, possibly indicating a higher degree of 
maturation. Indeed, their endothelial origin would be in agreement with the earliest progenitors 
expressing the marker. Additionally, this would confirm previous studies showing that HSCs 
emerging in the AGM express CDH5, which is downregulated upon maturation (Ivanovs et al., 
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2014a). Similarly, I showed that erythroid progenitors devoid of CDH5 produce a higher 
number of mature CFU-E colonies, and therefore appear to represent more committed 
progenitors. The expression of CDH5 on less mature erythroid cells suggests that they are 
possibly derived from CDH5+ HPCs. 
In conclusion, the combination of scRNAseq and in vitro differentiation of hPSCs gave me 
a detailed picture of developmental events which would be otherwise difficult to access in 
human. Furthermore, this approach allowed me to solve the complexity of this heterogeneous 










A key observation generated by our single cell analyses is the potential difference in 
proliferation between the distinct populations generated. In agreement with this, from 
morphological observations cell cycle appeared to be dynamic during the second stage of the 
differentiation protocol, as cells in this culture system initially seemed to show very little 
amount of proliferation between EHT D0 and EHT D2, while their proliferation increased after 
EHT D3 when clusters of haematopoietic cells started to appear, similar to the IAHCs found in 
vivo during development. Subsequently, single cells released in culture from these clusters after 
EHT D5 showed an extremely high proliferation rate. A dynamic regulation of the cell cycle 
machinery was also suggested by qPCR data, showing that cell cycle regulators were 
differentially expressed over time during EHT. To quantify all these observations, we decided 
to use our single cell transcriptomic data to examine the cell cycle state of the different 
populations involved in EHT. This approach suggested a role for cell cycle regulation in the 
generation of early HSPCs, which was further confirmed through functional validations. 
Overall, these results suggest an additional layer of complexity in the regulation of early 
haematopoiesis. 
 
4.2 Populations involved in EHT show distinct cell cycle states 
 
As previously shown, qPCR analyses of gene expression during the second stage of 
differentiation was able to give a first representation of EHT, with the expression of endothelial 
and haematopoietic genes showing an inverse correlation during the transition. Similarly, the 
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expression of key genes controlling cell cycle was in agreement with morphological 
observations, suggesting a dynamic behaviour for proliferation and cell cycle regulation (Figure 
4.1). Specifically, I could note the transcriptional upregulation of factors involved in S and 
G2/M phases and indicative of active cell cycle, including cyclin E1, cyclin B1, CDK2 and CDK1, 
and at the same time the transcriptional downregulation of proteins known to act as inhibitors 
of cell cycle progression, such as RB1, RBL2/p130 and CDKN1C/p57. Altogether, this data 
suggested a progressive increase in the number of cells entering the cell cycle, with a timing that 
corresponded to EHT progression. 
 
Figure 4.1 Expression of cell cycle regulators during EHT. The expression of key cell cycle genes was 
measured during EHT by qPCR. Results represent n=3 independent experiments, with error bars ±SEM.  
 
Prompted by these observations, we decided to interrogate our scRNAseq dataset and 
to investigate the cell cycle state of the previously identified populations. By calculating cell cycle 
phase scores based on canonical conserved markers, we were able to infer the cell cycle phase 
of individual cells in each cluster (Butler et al., 2018). The results showed a heterogeneous but 
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cell type-specific distribution in distinct cell cycle phases across different clusters (Figure 4.2). 
Endothelial cells were particularly enriched in G1, with almost 90% of the cells found in this 
phase. Mesenchymal cells and HPCs appeared to have a more active cell cycle, with HPCs still 
fairly enriched in G1. On the other hand, erythroid progenitors showed a completely opposite 
behaviour compared to endothelial cells, being characterized by an incredibly active cell cycle 
with only 2.5% of the cells in G1.  
 
Figure 4.2 Cell cycle analysis of populations involved in EHT. (A) Cell cycle scores for individual cells were 
calculated based on the expression of canonical marker genes, and cells were painted to graphically portray 
their cell cycle phase, both in the tSNE space and in the pseudotime trajectory. (B) The analysis revealed that 
distinct clusters are characterised by very distinct cell cycle distributions. 
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The analysis confirmed our previous observations and also suggested a potential 
connection between cell identity and cell cycle state. HECs generated in this system appeared 
either to be a population of quiescent cells or to be characterized by a low proliferation rate, and 
their transition to the haematopoietic compartment appeared to be tightly connected with the 
acquisition of an active cell cycle state. Furthermore, once generated, HPCs appeared to be 
actively cycling, a property which became drastically more prominent in the erythroid 
progenitors. 
These differences were further explored by comparing distinct clusters for the 
expression of specific regulators controlling the cell cycle state (Figure 4.3). With this approach 
we could see that compared to other clusters, endothelial cells were enriched for the expression 
of genes belonging to the Rb and CIP/KIP families, such as RB1, RBL2/p130, CDKN1A/p21 and 
CDKN1C/p57. These factors act by inhibiting G1 progression and G1/S transition, as previously 
discussed (Chapter 1.8.2). Overall the expression of these genes was consistent with an 
enrichment of the cells in G1 and a slow proliferation or quiescent phenotype. In contrast to 
this, both the haematopoietic clusters showed a lower expression for these cell cycle inhibitors, 
and especially the erythroid progenitors appeared to be enriched for factors like cyclin A2, 
usually expressed in dividing cells, or MKI67, a marker of proliferation. 
It was also interesting to note a differential expression for cyclin D genes, necessary for 
the activation of CDK4/6 and progression through the G1 phase. Endothelial cells were indeed 
enriched for cyclin D1 and D2, while both the haematopoietic clusters showed a preferential 
expression of cyclin D3, possibly suggesting a divergent requirement for cyclin D genes, 
although it is still unclear how the differential expression of specific cyclin D members might 
affect quiescence and progression through G1 phase. 
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Figure 4.3 Expression of cell cycle regulator genes on distinct clusters. The expression of key cell cycle 
regulators was assessed in distinct clusters based on scRNAseq data. 
 
 
To further confirm these results, I performed cell cycle profile analyses during EHT. For 
this, I collected samples at different time points during differentiation and performed staining 
for 5-ethynyl-2´-deoxyuridine (EdU) and DNA content. EdU is a nucleoside analogue to 
thymidine and is incorporated into DNA during active DNA synthesis, in this way effectively 
marking cells in S phase. DNA content instead allows discrimination between cells in G1 and 
G2/M. By combining this approach with staining for the CD43 surface marker, I was able to 
visualize by flow cytometry the cell cycle profile during EHT of cells in the haematopoietic and 
non-haematopoietic compartments (Figure 4.4). 
98 
The experiment confirmed that the emerging haematopoietic population was 
characterized by an active cell cycle profile, opposed to the non-haematopoietic fraction always 
containing a large majority of cells in the G1 phase. This was in agreement with the single cell 
transcriptomics data, and suggested a potential connection between cell cycle state and 
transition from endothelial to haematopoietic identity. Ultimately, this led me to the hypothesis 
that endothelial cells with haemogenic potential might reside in a quiescent or almost quiescent 
state, and that their engagement into haematopoietic commitment could be associated with, 





Figure 4.4 Cell cycle state during EHT. Using EdU staining assay, cell cycle state for CD43- and CD43+ 
fractions was monitored during EHT, confirming previous data from scRNAseq. Results represent technical 






4.3 Cell cycle progression is necessary for the specification of 
functional HPCs 
 
Following this data, I decided to investigate whether cell cycle progression was not only 
associated with, but also necessary for, EHT. For this, I used the small molecule Nocodazole, an 
antimitotic agent that acts by binding to β-tubulin and therefore disrupting the polymerization 
of microtubules. This leads to an inhibition of microtubule dynamics, and ultimately to 
disruption of mitotic spindle function and arrest of the cell cycle in the G2/M phase (Blajeski et 
al., 2002). I started a treatment with 0.1 μg/mL Nocodazole at EHT D3 and collected the cells 
after 48 hours at EHT D5. The cell cycle profile was once again determined through EdU 
staining, showing an expected enrichment for cells in G2/M following the treatment. 
Surprisingly, the assay also revealed that a significant fraction of cells were still found in G1, 
probably representing cells that during the 48 hours treatment never entered the cell cycle, 
therefore not reaching the G2/M phase to be affected by Nocodazole (Figure 4.5A). Considering 
data previously shown, this population of cells which appeared to be blocked in G1 likely 
represented endothelial cells. And given the length of the treatment with Nocodazole, this 
suggested that these cells remained in G1 for at least 48 hours, therefore likely defining a 
quiescent population.  
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Figure 4.5 Cell cycle progression is necessary for HPCs specification. Cells were differentiated as previously 
described, and at EHT D3 media was supplemented either with 0.1% DMSO (CTRL) or with 0.1 μg/mL 
Nocodazole (Noc). After 48h at EHT D5, cells were either (A) processed for EdU and CD43 staining, or (B) 
alternatively they were washed to remove Nocodazole and further cultured in a CFU assay. Results represent 
n=3 independent experiments, with error bars ±SEM, and statistical significance compared to control as 
*P<0.5, **P<0.01, ***P<0.001, ****P<0.0001 by unpaired t-test. 
    
Additionally, the experiment showed a decrease in CD43+ cells, suggesting a reduction 
`in the number of haematopoietic cells generated as a consequence of the treatment. As 
previously noticed, scRNAseq data and cell cycle profile analysis had shown that 
haematopoietic cells, especially erythroid progenitors, had an active cell cycle. Therefore, one 
possibility for the reduced number of CD43+ cells was that Nocodazole had simply blocked 
proliferation of haematopoietic cells once produced, without affecting their generation. In order 
to test this possibility, samples were collected after treatment and washed to remove 
Nocodazole, therefore releasing them from the cell cycle block. These cells were then used for a 
CFU assay to assess their capacity to terminally differentiate. If the effect of the treatment was 
limited to cell proliferation, the assay would have shown haematopoietic colonies, although 
with reduced numbers. Instead, the experiment showed that treated cells barely had any blood 
colony forming potential despite the presence of CD43+ cells, revealing that blocking cell cycle 
progression did not only affect proliferation of progenitors already generated, but the EHT 
process itself and the effective specification of these progenitors (Figure 4.5B). As a result, these 
cells had not acquired full haematopoietic competence and capacity to further differentiate into 
committed lineages. Based on these results, it is possible that the cell cycle state might control 
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key mechanisms necessary for the acquisition of full haematopoietic functionality, and that a 
normal cell cycle progression is fundamental and necessary to correctly complete EHT and for 
the generation of functional HPCs. 
 
4.4 Dissection of endothelial subpopulations involved in EHT 
 
Transcriptomic data and functional experiments confirmed a role for cell cycle 
progression in EHT. It was clear though that the endothelial cluster itself was heterogeneous, as 
already indicated by the non-uniform expression of key marker genes or transcription factors 
necessary for HSPC specification (Figure 3.2, Figure 3.3). Of note, the pseudotime trajectories 
also showed that these cells constitute a continuum from the endothelial state along their 
progression to the branch point and beyond to the mesenchymal and haematopoietic lineages 
(Figure 3.8). Therefore, an intriguing possibility was that endothelial cells found at different 
points along the trajectory might represent distinct endothelial states, with differences between 
these states potentially revealing important information about the transition. This would allow 
to distinguish endothelial cells engaged in EHT and committed to the haematopoietic fate from 
cells retaining a pure endothelial identity. 
For this analysis, we used the pseudotime previously generated but we focused uniquely 
on endothelial cells, removing the remaining 3 clusters. As a result, endothelial cells were 
divided into 4 subclusters based on their relative position along the trajectory (Figure 4.6). With 
this approach, we were able to compare the expression of key marker genes across these 
different endothelial subpopulations. In confirmation of the pseudotime trajectory as 
representative of a progressive exit from the endothelial state, we could observe dynamic 
expression of endothelial markers such as CDH5 or PECAM1. It was also interesting to note 
that subcluster D not only showed lower expression of endothelial genes, but also the 
concomitant expression of markers like KRT8 and TAGLN. This was consistent with their 
allocation to the portion of the pseudotime trajectory previously shown to correspond to the 
mesenchymal cluster (Figure 3.8), suggesting these cells to represent endothelial cells 
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transitioning to the mesenchymal fate. Importantly, a different behaviour was observed on 
subcluster C, which also showed downregulation of endothelial markers, but this time not 
coincidental with the expression of haematopoietic markers, which were either only weakly 
upregulated, like for MYB, or at the same level compared to subcluster A, as was the case for 
RUNX1. This observation could suggest that in HECs undergoing EHT, downregulation of 
endothelial factors and loss of endothelial identity needs to happen before the upregulation of 
haematopoietic factors can take place, shedding light on a possible temporal sequence of events 
which in vivo leads to the specification of early HSCs. However, additional experiments aimed 
at further elucidating these temporal changes taking place during EHT will be necessary, as 
previous studies have instead shown that RUNX1 is responsible for the upregulation of GFI1 
and GFI1B, which in turn cause the repression of endothelial genes (Lancrin et al., 2012).  
Based on my previous results showing a distinct cell cycle state for endothelial cells and 
the haematopoietic compartment, I decided to investigate whether these distinct endothelial 
subpopulations might also show a differential enrichment for specific cell cycle regulators 
(Figure 4.7). This analysis revealed that cells in subcluster A were characterized by a higher 
expression of cell cycle inhibitors of the Rb and CIP/KIP families, similarly to what we had 
previously shown for the totality of endothelial cells compared to other cell types. On the other 
hand, the group of endothelial cells in subcluster C, supposedly the most advanced along 
haematopoietic commitment, had lower levels of these regulators, at the same time without any 
sign of upregulation of proliferation markers such as MKI67 or cyclin A2. Importantly, this 
might indicate that the downregulation of cell cycle inhibitors is the first event required for 




Figure 4.6 Analysis of endothelial subclusters. The endothelial cluster was further divided, and subclusters 
were characterised for the expression of endothelial and mesenchymal markers, along with transcription 




Figure 4.7 Expression of cell cycle regulator genes in endothelial subclusters. The expression of key cell 





In this chapter, I showed that the dynamic regulation of the cell cycle progression is 
associated with the control of haematopoietic specification. Indeed, prompted by 
morphological observations and qPCR results, a deeper analysis of the cell cycle state was 
performed by interrogating our single cell transcriptomics data. The analysis revealed how the 
distinct cell types previously identified were also characterized by peculiar cell cycle states, the 
two extremes being quiescent endothelial cells and extremely proliferating erythroid 
progenitors. This in silico analysis was functionally confirmed and further expanded by 
experiments in which blocking cell cycle progression appeared to reduce the number of CD43+ 
cells. One obvious explanation for this reduction upon cell cycle arrest would be a lack of 
proliferation in the haematopoietic fraction, especially considering that the erythroid 
progenitors had a high proliferative cell cycle profile and their number quickly expanded over 
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time, as previously shown (Figure 3.8). However, proliferation could not entirely explain the 
phenotype observed. Indeed, upon treatment with Nocodazole, cells displayed an almost 
complete lack of blood colony forming potential, suggesting that blocking cell cycle progression 
during EHT might impair the generation of functional haematopoietic cells. Therefore, the 
CD43+ cells produced in the presence of the cell cycle blocker appeared to be qualitatively 
different, and possibly represented progenitors that emerged from EHT but failed to acquire 
the capability to further differentiate. This would suggest that key molecular mechanisms 
necessary for the correct specification of functional progenitors are cell cycle dependent. In this 
regard, our group has previously shown that hPSCs acquire responsiveness to distinct 
differentiation signals during specific phases of the cell cycle, through a post-translational 
modulation of SMAD2/3 transcriptional activity controlled by cyclin D-CDK4/6 (Pauklin and 
Vallier, 2013). Similarly, it is possible that during EHT the cells need to transition through 
specific cell cycle phases to activate mechanisms that are required for the acquisition of 
haematopoietic functionality. Of note, my data showed that distinct groups of cells had different 
requirement for cyclin D members, with endothelial cells enriched for cyclin D1/D2 and 
haematopoietic clusters preferentially expressing cyclin D3. This might suggest a role for cyclin 
D-CDK4/6 in controlling developmental mechanisms during EHT. In this regard, further 
investigations might reveal that distinct cyclin D proteins possibly modulate this activity 
through stage- or cell type-specific mechanisms. 
In agreement with my results showing EHT to be associated with the acquisition of an 
active cell cycle profile, it was recently reported that the earliest haematopoietic progenitors 
generated in the mouse AGM are slowly cycling cells, and that their maturation is associated 
with the acquisition of a more active cell cycle (Batsivari et al., 2017). Furthermore, the 
anatomical position of these cells within IAHCs appears to be correlated with their cell cycle 
state, with slowly cycling cells frequently found at the base of the cluster in association with the 
underlying endothelium and rapidly cycling cells located at more apical positions. Our results 
agree with this observation and further expand it. Indeed, my data suggested that endothelial 
cells are quiescent and enter the cell cycle upon commitment to the haematopoietic fate, and 
additionally I showed that cell cycle progression might be necessary for this transition, possibly 
revealing a tight link between the molecular machineries controlling cell cycle state and cell fate 
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decision during EHT. In this regards, I also showed that endothelial cells are enriched for the 
expression of cell cycle inhibitors, such as members of the CIP/KIP family. These regulators 
might actively prevent endothelial cells from entering the cell cycle and undergoing EHT, and 
only those cells in which they are successfully downregulated might be able to start the 
transition. Importantly, these regulators have been reported to be modulated by TGFβ 
signalling and induce cell cycle exit of LT-HSCs after their migration to the foetal liver (Hur et 
al., 2016). Therefore, the inhibition of this signalling pathway in vitro could instead allow the 
downregulation of these cell cycle inhibitors and potentially increase the number of endothelial 
cells undergoing EHT, thus improving the efficiency of differentiation. However, the accurate 
temporal regulation of the pathway might be essential, as an excessive activation of the cell cycle 
could potentially make the HPC state even more transitory and rapidly cause their further 
commitment. 
In support to the hypothesis of the cell cycle activation as a molecular requirement for 
EHT, further dissection of the endothelial cluster revealed that endothelial cells at the beginning 
of the pseudotime trajectory were enriched for the expression of these cell cycle inhibitors, 
consistent with a quiescent state or very slow cell cycle progression. On the other hand, 
endothelial cells that localised at the onset of the haematopoietic branch on the trajectory, and 
thus likely to represent cells actively engaged in EHT, were revealed to have downregulated such 
inhibitors but to not yet express proliferation markers. These cells could potentially represent 
an intermediate state, likely very transitory, in which endothelial markers have started to be 
transcriptionally downregulated, despite a lack of haematopoietic genes upregulation, possibly 
temporally subsequent. Based on these results, I hypothesise that haemogenic endothelial cells 
are normally kept in a quiescent state by the expression of cell cycle inhibitors. The first 
requirement for the onset of EHT would then be the removal of these molecular breaks to allow 
cell cycle entry and progression. This would be necessary for endothelial cells to start the 
transition to the haematopoietic fate, associated with the transcriptional downregulation of 
endothelial genes and acquisition of haematopoietic transcriptional identity. 
In conclusion, cell cycle progression appears to be necessary for endothelial cells to start 
EHT and for the acquisition of full functionality and blood forming capacity. Mechanistically, 
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one possibility is that cell cycle progression is required for the cells to become responsive to 
specific signals and for the activation of differentiation mechanisms. In this context, 
understanding signalling pathways driving the cell cycle entry could help improve the 











5 CYCLIN-CDK COMPLEXES LINK CELL CYCLE 





In the previous chapter, I unveiled how cell cycle and haematopoietic specification are 
tightly co-regulated. Cell cycle entry of HECs appeared to be limited to cells undergoing EHT 
and committing to blood lineages, while cell cycle progression was shown to be essential for the 
correct generation of haematopoietic cells. Based on these findings, I decided to further explore 
the connection between cell cycle regulation and haematopoietic commitment. For that, I 
focused on the role of CDK proteins during EHT. CDKs are the effector subunits of key 
regulators of the cell cycle progression that act during checkpoints in G1/S and G2/M upon 
binding to their regulatory cyclins. Importantly, CDKs have also been shown to possess a variety 
of non-canonical functions and to be important for other processes such as differentiation. In 
pancreatic progenitors, lengthening of the G1 phase was shown to be necessary for the complete 
induction of NEUROG3, essential for endocrine development. Upon cell cycle entry, the G1/S 
kinases CDK4/6 and CDK2 were suggested to phosphorylate NEUROG3, causing its 
subsequent degradation and ensuring that endocrine differentiation only occurs in non-
dividing cells (Krentz et al., 2017). CDK5 was reported to have a neuroprotective role by 
promoting cell cycle arrest in neurons, but also to regulate through its kinase activity other 
events during development of the nervous system, including neuronal migration and axon and 
dendrite development (Zhang et al., 2010; Su and Tsai, 2011). Furthermore, CDK4/6 can direct 
early cell fate decisions in hPSCs by controlling the transcriptional activity of key transcription 
factors such as SMAD2/3, therefore determining cell fate propensity towards mesendoderm or 
neuroectoderm (Pauklin and Vallier, 2013). Based on my results revealing a link between cell 
cycle progression and haematopoietic differentiation, CDKs might have a similar role during 
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EHT in controlling specification of early HSPCs during development. Therefore, I decided to 
investigate the role of these regulators. 
 
5.2 Functional effect of CDK inhibitors during EHT 
 
As previously discussed (Chapter 1.8.2), CDKs are master regulators of the cell cycle 
which are activated by cyclins specifically expressed at different phases. Importantly, this 
specific expression allows for the temporary activation of cyclin-CDK complexes at distinct cell 
cycle phases. To study the role of these regulators during EHT, I took advantage of three small 
molecules, well-characterised inhibitors of cyclin-CDK complexes (CDKi) which bind to 
distinct CDK proteins and block their phosphorylation activity (McInnes, 2008; Figure 5.1).  
 
Figure 5.1 Inhibition of cyclin-CDK function by small molecules. For the study I have used the small 
molecules PD0332991, Roscovitine and RO3306, inhibitors of CDK4/6, CDK2 and CDK1, respectively. 
 
PD0332991 inhibits CDK4 and CDK6 (Finn et al., 2009; Rocca et al., 2014), both of 
which form complexes with cyclin Ds and phosphorylate Rb proteins to enable progression 
through G1 phase. RO3306 inhibits CDK1 (Vassilev, 2006; Prevo et al., 2018) which interact 
with cyclin Bs and cyclin As for the progression through G2/M. The main Roscovitine target is 
CDK2 (Vella et al., 2016), which upon binding to cyclin Es and cyclin As leads to G1/S transition 
and progression through the S phase. This molecule has also been reported to inhibit CDK1, 
although with lower affinity (Meijer et al., 1997; Knockaert et al., 2000).  
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Figure 5.2 Effect of CDK inhibitors during EHT. Samples were treated with either of the three small 
molecules or with 0.1% DMSO (CTRL) for 48 hours between EHT D3 and EHT D5. (A, B) As shown by EdU 
staining, the treatments caused an expected change in the cell cycle profile: enrichment of cells in G1 phase 
for the CDK4/6 inhibitor PD0332991 (1 μM); very limited increase in both G1 and G2/M for the CDK2/1 inhibitor 
Roscovitine (4 μM); increase in G2/M phase for the CDK1 inhibitor RO3306 (10 μM). (C) This was associated with 
a decrease in the number of CD43+ cells for samples treated with CDK4/6i and even more with CDK1i, as 
assessed by flow cytometry. (D) Most importantly, the treatment affected the blood colony forming potential 
upon CFU assay. CDK4/6i caused a significant decrease in the number of erythroid colonies, particularly of the 
BFU-E type. CDK2/1i caused an increase, although not significant, in the number of mature CFU-E erythroid 
colonies. Most importantly, CDK1i caused the greatest effect, with significant disruptions in both the erythroid 
and myeloid colonies. Of note, both CDK4/6i and CDK1i had an important effect on the number of CFU-GEMM 
colonies derived from multipotent progenitors. Results in (B) and (C) represent n=2 independent experiments, 
one of which is shown in (A), and error bars are ±SEM. Results in (D) represent n=3 independent experiments, 
with error bars ±SEM, and statistical significance compared to control as *P<0.5, **P<0.01, ***P<0.001 by one-
way ANOVA. 
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As for previous experiments, cells were differentiated until EHT D3 and then grown in 
the presence of one of the inhibitors for 48 hours. At EHT D5 cells were collected for further 
analyses. Specifically, I assessed their cell cycle profile by EdU staining, the number of CD43+ 
cells produced by flow cytometry and, upon removal of the inhibitors, their blood colony 
forming capacity by CFU assay. The results revealed interesting effects which appeared to be 
specific for distinct treatments (Figure 5.2).  
The inhibition of CDK4/6 (CDK4/6i) caused an expected enrichment of cells in the G1 
phase, a reduction in the number of CD43+ cells, and an overall reduction in the number of 
colonies generated in CFU assay, especially of the erythroid lineage. This effect would be 
consistent with my previous results showing that cell cycle entry is necessary for correct EHT. 
In this context, the inhibition of CDK4/6 would possibly limit endothelial cells exiting G1 phase 
or delay their transition to the S phase, therefore preventing them from engaging EHT and 
reducing the number of haematopoietic progenitors generated.  
Treatment with Roscovitine did not cause major disruptions in the cell cycle profile, as 
shown by a limited increase in the number of cells found in the G1 and G2/M phases. 
Nevertheless, the fact that this small increase was observed in these two phases seemed to 
confirm that this molecule affected both CDK2 and CDK1 (CDK2/1i). This limited change in 
cell cycle profile was associated with a very small decrease in the number of CD43+ cells and 
with an increase, although not significant, in the number of CFU-E colonies, representative of 
more mature erythroid progenitors, possibly suggesting an increased commitment towards this 
lineage. 
Finally, the inhibition of CDK1 (CDK1i) blocked the cell cycle in the G2/M fraction, 
decreased the CD43 compartment and reduced the number of BFU-E and myeloid colonies. 
Furthermore, both the inhibition of CDK1 and CDK4/6 caused a depletion in the number of 
multilineage CFU-GEMM colonies. My previous data (Figure 3.7) showed that myeloid and 
multilineage colonies were specifically derived from the small cluster labelled as multipotent 
HPCs in the scRNAseq tSNE plot. Therefore, this would suggest the two molecules to possibly 
affect generation, self-renewal and/or commitment capacity of this specific population, with the 
inhibition of CDK1 being the most detrimental treatment. 
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In order to further investigate the effect of the CDK inhibitors on EHT, I compared the 
expression of key marker genes by qPCR at EHT D5 after a 48 hours treatment (Figure 5.3, 
Figure 5.4). This approach showed only mild differences, the strongest being achieved with the 
inhibition of CDK4/6. Specifically, I could observe a small increase in the expression of the 
endothelial markers VWF, PECAM1 and CDH5 upon this treatment, and at the same time a 
limited decrease in HSC genes like MYB and RUNX1. This would be consistent with a delayed 
G1 exit causing reduced EHT transition and thus an enrichment in endothelial cells. In 
agreement with this hypothesis, I could also observe an increase in the expression of cyclin D1 
and D2, which I had previously shown through scRNAseq to be more expressed on endothelial 
and mesenchymal cells, while haematopoietic cells were relying more on cyclin D3 (Figure 4.3).  
However, these differences were very limited and gene expression measured on a 
population level by qPCR could not reveal important effects induced by inhibition of CDK 
regulators. This observation could be explained by the heterogeneous nature of the culture 
system. Indeed, different cell types participating in the transition could be differentially affected 
by the treatments and contribute in distinct ways to the phenotypes. For this reason, I decided 
to perform scRNAseq to capture differences between intermixed cell types and therefore 














Figure 5.3 Expression of key marker genes by qPCR upon treatment with CDK inhibitors. The expression 
of key haematopoietic and endothelial genes upon treatment with CDKi was measured at EHT D5 by qPCR. 













Figure 5.4 Expression of cell cycle regulator genes by qPCR upon treatment with CDK inhibitors. The 
expression of key cell cycle regulators upon treatment with CDKi was measured at EHT D5 by qPCR. Results 










5.3 Single cell transcriptomics reveal disruptions in cluster 
organisation and cell cycle state upon inhibition of CDKs 
 
Cells were grown for 48 hours starting at EHT D3 in the presence of specific CDK 
inhibitors or in the presence of 0.1% DMSO. The resulting cells collected at EHT D5 were then 
processed for scRNAseq. Data was analysed as previously described (Chapter 3.2), combining 
the four samples and clustering in the 3D tSNE space (Figure 5.5). By combining and analysing 
the samples together, it was possible to detect the 4 clusters previously identified and compare 
each cell population across different conditions. Using this approach, I could observe that the 
relative population frequencies were specifically affected by distinct treatments (Figure 5.6).  
 
 
Figure 5.5 Clustering in the tSNE space of samples upon different treatments. Samples treated with either 
of the three small molecules or with DMSO were processed for scRNAseq. Data for the four samples was 





Figure 5.6 Effect of CDK inhibitors on the tSNE generated clusters. The analysis allowed to observe the 
effect of CDKi during EHT with single cell precision and to directly compare equivalent clusters across samples. 
The treatments appeared to affect the distribution of the populations previously described. 
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These results showed enrichment in endothelial cells upon CDK4/6 inhibition. This 
change was associated with a decrease in the haematopoietic compartment, specifically for the 
erythroid progenitors, consistent with previous CFU results (Figure 5.2D). Interestingly, the 
population of HPCs did not appear to be reduced but instead slightly increased. This was not 
consistent with the observed decrease in the CFU assay in the number of multilineage colonies, 
known from previous data to derive exclusively from this cluster (Figure 3.7). This suggested 
that beyond affecting the proliferation of erythroid progenitors, the inhibition of CDK4/6 might 
be affecting the generation of functional HPCs or their ability to further differentiate.  
The CDK2/1 inhibitor did not cause major differences in the number of cells belonging 
to each cluster compared to control, consistent with the fact that at the functional level, except 
for a limited increase in the number of CFU-E colonies, this treatment was the least disruptive. 
On the other hand, cells grown in the presence of the CDK1 inhibitor were strongly 
affected. Indeed, I could observe an increased number of endothelial cells concomitant with a 
decrease in the haematopoietic compartment. Moreover, this treatment was the most 
detrimental for the HPC cluster. This was in agreement with previous results showing that the 
treatment caused a reduced number of myeloid and multilineage colonies, which are derived 
from this population (Figure 5.2D, Figure 3.7). Thus, these results appeared to suggest an 
important role for CDK1 in these early multipotent progenitors, possibly affecting their 
generation or self-renewal. 
Of note, none of the treatments caused major changes in the size of the mesenchymal 
cluster, possibly indicating that the cell cycle regulation is specifically important for EHT but 
not for EndoMT.  
Additionally, the transcriptomics data was analysed to examine the cell cycle 
distribution of individual cell clusters in each sample (Figure 5.7). One possibility was indeed 
that distinct cell types would be affected with different specificity by CDK inhibition. As 
previously shown, we determined the cell cycle state of individual cells based on the expression 
of canonical marker genes, and compared corresponding clusters across different conditions. 
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Figure 5.7 Cell cycle profile of distinct clusters in the combined dataset. Cell cycle marker genes identified 
in the scRNAseq dataset were used to calculate cell cycle scores. 
 
As expected and in agreement with EdU staining (Figure 5.2A,B), the inhibition of 
CDK4/6 caused an enrichment of cells in G1 (Figure 5.8). More precisely, the treatment 
increased the number of endothelial cells found in G1 to almost 97%.  Thus, it appeared that 
the inhibition of CDK4/6 could prevent or delay their cell cycle entry and possibly prevent them 
from undergoing EHT. This would explain the observed increase in the endothelial fraction 
compared to control (Figure 5.6). Importantly, an increase in the number of cells in the G1 
phase was also shown for both the HPC and erythroid clusters, the latter previously shown to 
be decreased in its size upon treatment. These profiles and the relative cluster frequencies might 
suggest that endothelial cells produce erythroid progenitors through a highly transitory HPC 
population, and that blocking CDK4/6 affects this process.  
Overall, these results explain the reduction in the number of CD43+ cells and of colonies 
produced in the CFU assay, especially of the erythroid lineage (Figure 5.2). At the same time, 
multilineage CFU-GEMM colonies were shown to derive exclusively from HPCs, whose cluster 
size was not depleted by the treatment. Therefore, this would suggest that the reduced number 
of this type of colony was entirely dependent on an altered capacity to differentiate as a 
consequence of CDK4/6 inhibition, rather than decreased HPC production. 
120 
 
Figure 5.8 CDK4/6i cell cycle profiles. The cell cycle profile of individual clusters upon inhibition of CDK4/6 




Figure 5.9 CDK2/1i cell cycle profiles. The cell cycle profile of individual clusters upon inhibition of CDK2/1 
was calculated based on transcriptomics data and compared to the control condition. 
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In contrast to this, the inhibition of CDK2/1 caused overall a less intense effect and the 
cell cycle profile of the endothelial cluster was essentially unaffected (Figure 5.9). The main 
differences appeared on the multipotent HPC cluster and, on a lesser extent, the erythroid 
progenitors. A limited enrichment in S phase at the expenses of G2/M was observed in the 
erythroid cells suggesting a specific effect of the inhibitor on CDK2 for this particular 
population. On the other hand, the treatment increased both S and G2/M phases in the HPC 
cluster, suggesting that in this specific population the inhibitor could affect both CDK2 and 
CDK1. Nevertheless, considering these and previous results, the effect of this treatment 
appeared to be overall very limited, both at the transcriptional and functional level. 
Finally, the inhibition of CDK1 caused an expected enrichment in G2/M for the 
endothelial cluster (Figure 5.10). Given the key function of CDK1 in G2/M, it appeared that the 
cells blocked in this phase were endothelial cells engaged in cell cycle progression, possibly 
representing cells undergoing EHT, as previously discussed (Chapter 4.5). Accordingly, upon 
CDK1 inhibition I observed a reduction in the number of multipotent HPCs, whose number 
was uniquely affected by this treatment. Nevertheless, I previously assessed the presence of 
HPCs already at EHT D3 (Figure 3.8), the time when the CDK1 inhibitor was applied. This 
would suggest that beyond a possible influence over the generation of new HPCs from 
haemogenic endothelial cells, the treatment might also affect previously generated progenitors, 
possibly altering their survival or self-renewal capacity, for example promoting their further 
differentiation and exhaustion. This might confirm that the HPC population is normally very 
transitory and that their further differentiation is associated with cell cycle progression. 
Consequently, the inhibition in G2/M might promote their commitment. Indeed, the analysis 
showed that the remaining HPCs were enriched in the G1 phase, possibly suggesting that these 
cells need to progress through the cell cycle to differentiate and that instead they retain an 
undifferentiated state in G1. This would be in agreement with previous results showing that the 
HPC cluster is instead preserved and slightly enriched when CDK4/6 is inhibited (Figure 5.8), 
although in this case their ability to further differentiate was affected. Furthermore, the cell cycle 
of the erythroid progenitors was surprisingly not enriched in G2/M phase, possibly suggesting 
functional redundancy in this specific cell type.   
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Figure 5.10 CDK1i cell cycle profiles. The cell cycle profile of individual clusters upon inhibition of CDK1 was 
calculated based on transcriptomics data and compared to the control condition. 
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5.4 CDK inhibition differentially affects gene expression of 
distinct clusters  
 
As previously mentioned, cell cycle regulators have been shown to have multiple roles 
beyond their control over cell cycle progression (Hydbring et al., 2016) and to direct 
differentiation and cell fate decision in multiple systems (Zhang et al., 2010; Su and Tsai, 2011; 
Pauklin and Vallier, 2013; Krentz et al., 2017). Therefore, it is possible that the CDK role in 
specification and further differentiation of in vitro generated haematopoietic progenitors might 
be related not uniquely to their function in cell cycle progression but also associated with 
secondary roles performed by these regulators. Ultimately, the inhibition of CDK function 
might possibly affect signalling pathways or other molecular mechanisms taking place during 
EHT.  
To investigate this possibility, I compared differentially expressed genes for each cluster 
across distinct treatments. For this analysis, only genes showing a differential expression greater 
than 0.5 log2 fold changes were considered, and I used the Enrichr resource to perform gene 
ontology (GO) analysis and determine biological processes involving such differentially 
expressed genes (Kuleshov et al., 2016). This approach showed small changes in specific clusters 
in the expression of a variety of genes.  
Upon inhibition of CDK4/6, each cluster compared to control showed downregulation of 
genes for ribosomal subunits or enrichment in GO terms involved in mitochondrial 
functioning, possibly consistent with a reduced translational and metabolic activity as a 
consequence of a slowed cell cycle progression (Figure 5.11, Table 5.1 to Table 5.6). At the same 
time, the haematopoietic clusters showed a limited upregulation of genes associated with 
membrane reorganization and exocytosis. Of note, the multipotent HPC cluster upon 
treatment showed a small increase in few haemoglobin genes, possibly suggesting a priming 
toward the erythroid lineage. 
  On the other hand, the very limited functional effect on differentiation and cell cycle 
profile observed for samples treated with the CDK2/1 inhibitor was reflected by their 
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transcriptional signature, as almost all the clusters showed no or very little change (Figure 5.12, 
Table 5.7). The only relevant effect was observed on the HPC cluster, showing upregulation of 
erythroid genes such as ALAS2 and haemoglobins, along with the platelet factors PPBP and PF4. 
This would be in agreement with the increase in mature erythroid CFU-E colonies found in the 
CFU assay, although that increase was not statistically significant (Figure 5.2).  
Finally, the inhibition of CDK1 caused downregulation of ribosomal subunits and of 
genes enriched in GO terms associated with mitochondrial functions, together with the 
downregulation in HPCs of factors involved in gene expression and mRNA processing (Figure 
5.13, Table 5.8 to Table 5.14). This could be possibly associated once again with a reduced 
cellular activity caused by the enrichment in G2/M and delayed cell cycle progression. In 
agreement with this effect on the cell cycle, the upregulation of genes associated with mitosis, 
cytoskeleton rearrangement and G2/M transition was observed in the endothelial population. 
In addition, the cluster of multipotent HPCs showed upregulation of the erythroid ALAS2 and 
haemoglobin genes, with downregulation of the myeloid factor MPO, in agreement with the 
lack of myeloid potential observed in the CFU assay. Interestingly, inhibition of CDK1 also 
caused in this cluster the upregulation of MALAT1, NEAT1 and TXNIP, previously reported to 
crosstalk with the MAPK signalling in endothelial cells and mediate the cellular response to 
stress conditions like oxidative stress (Li et al., 2009; Liu et al., 2014; Fuschi et al., 2017; Tian et 
al., 2017). Some of these factors were also upregulated in erythroid (MALAT1 and NEAT1) and 
endothelial cells (NEAT1). Overall, the upregulation of these genes, along with the 
downregulation of genes associated with mitochondrial functions, potentially suggested that 
the inhibition of CDK1 promote the cell response to stress.  
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Figure 5.11 CDK4/6i differentially expressed genes per cluster. Differentially expressed genes between 
treatment and control are shown in these regression plots divided by cluster. For each gene and on each 
sample, axes are log2 of the average counts. Differentially expressed genes are highlighted. Genes falling into 
the diagonal are not considered as differentially expressed. Cut-off used is log2 fold change = 0.5. 
 
 
Figure 5.12 CDK2/1i differentially expressed genes per cluster. Differentially expressed genes between 
treatment and control are shown in these regression plots divided by cluster. For each gene and on each 
sample, axes are log2 of the average counts. Differentially expressed genes are highlighted. Genes falling into 




Figure 5.13 CDK1i differentially expressed genes per cluster. Differentially expressed genes between 
treatment and control are shown in these regression plots divided by cluster. For each gene and on each 
sample, axes are log2 of the average counts. Differentially expressed genes are highlighted. Genes falling into 






In this chapter I examined the role during EHT of key CDK proteins, master regulators 
of the cell cycle also involved in a variety of non-canonical functions, as previously discussed 
(Chapters 1.8.2 and 5.1). For this, I took advantage of three small molecules, well-characterised 
inhibitors which bind to the CDKs and block their function. With this approach, and by 
combining functional experiments and scRNAseq analyses, I was able to study the role of these 
regulators in the distinct populations participating in the transition.  
Based on these results, CDK4/6 appears important for endothelial cell entry into the cell 
cycle and commitment to the haematopoietic fate. Specifically, this regulator is necessary for 
G1 progression and transition to the S phase, and blocking its activity causes an expected 
enrichment in G1 for both the endothelial and haematopoietic compartments. In this context, 
the reduction in the number of erythroid progenitors might be explained in part by decreased 
proliferation. However, this is also associated with a concomitant increase in the number of 
endothelial cells, most likely as a result of their reduced transition to the haematopoietic fate. 
On the other hand, the number of multipotent HPCs is not affected and is instead slightly 
increased. Overall, these results suggest that endothelial cells undergoing EHT normally 
generate a population of multipotent HPCs which, in the current culture conditions, is highly 
transitory and quickly commit to the erythroid fate (Figure 5.14A). In this scenario, the activity 
of CDK4/6 appears to be required for both HPC generation and for erythroid differentiation 
and proliferation. This hypothesis is in agreement with the observed effects upon inhibition of 
CDK4/6, consisting in a reduced number of CD43+ cells, fewer erythroid colonies generated in 
the CFU assay, and decrease in the erythroid cluster concomitant with an increase in the 
endothelial population. Furthermore, this would be consistent with previous studies showing 
that the erythroid commitment is reinforced during the S phase by the repression of the myeloid 
transcriptional programme (Pop et al., 2010). In agreement with this, my results show that 
preventing cells from transitioning to the S phase causes a reduction in the erythroid lineage, 
therefore suggesting that a similar mechanism might take place in the generation of early 
erythroid progenitors during development. Accordingly, despite the size of the HPC cluster not 
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being affected, a reduction in the number of multilineage CFU-GEMM colonies is observed 
upon inhibition of CDK4/6. This might confirm that CDK4/6 activity and G1/S transition are 
necessary for erythroid, but not for myeloid, commitment, and that a longer G1 phase results 
in restricted commitment and therefore fewer multilineage colonies. To address this hypothesis, 
it will be necessary to isolate the HPC population and specifically test their potential upon 
inhibition of CDK4/6 by single cell differentiation experiments. This would also allow 
examination of the capacity of these progenitors to generate erythroid colonies upon CDK 
inhibition, currently masked by the presence in culture of erythroid cells generated before the 
treatment, and therefore to discriminate between HPC differentiation and erythroid 
proliferation. Importantly, the depletion of CDK4/6 activity does not affect the size of the 
multipotent HPC cluster and these cells do not accumulate despite their reduced differentiation, 
suggesting that beyond being necessary for their differentiation, CDK4/6 is also essential for 
endothelial cells to undergo EHT and generate more HPCs. Of note, it was previously reported 
that CDK6 can bind to RUNX1 and interfere with its transcriptional activity (Fujimoto et al., 
2007). RUNX1 is an essential regulator of EHT, which synergises with other key factors such as 
TAL1 and GATA2. It is necessary for the induction of the definitive transcriptional programme 
and its requirement in the AGM has been suggested to end after HSPC specification, as 
previously discussed (Chapter 1.7.5). Thus, it is possible that an important role for the cell cycle 
machinery is to modulate the timely activation of the haematopoietic transcriptional network, 
and in this context the inactivation of RUNX1 by CDK6 might be necessary for the completion 
of the haematopoietic specification. In agreement with this hypothesis, based on my results 
CDK4/6 activity, which is necessary for cell cycle entry and G1/S progression, also appears to 
be important during EHT for both HPC specification and further differentiation to the 
erythroid fate (Figure 5.14B). 
Similarly, CDK1 also appears to have an important role in endothelial cells during EHT. 
In agreement with its function in cell cycle progression, endothelial cells display an enrichment 
in the G2/M phase upon inhibition of CDK1. This results in an increased endothelial 
population, suggesting that CDK1 is necessary for their progression to the haematopoietic fate. 
Indeed, this corresponds to a reduction in the haematopoietic compartment, as also indicated 
by the lower number of CD43+ cells. However, the decrease is not limited to the erythroid 
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cluster as seen for CDK4/6, and instead involves also the population of multipotent HPCs, in 
agreement with the fewer myeloid and multilineage colonies observed in the CFU assay. This 
potentially highlights an essential role for CDK1 during EHT, with its activity being important 
for the generation of multipotent HPCs. In addition, the reduction in the number of HPCs 
might also depend on a role of CDK1 on their commitment, so that blocking HPC progression 
once the cell cycle has been engaged might be not able to prevent their further differentiation. 
Indeed, it is possible that the undifferentiated state of this transitory population can only be 
preserved in the G1 phase.  In this scenario, CDK1 would be essential for the completion of the 
cell cycle, thus allowing the progenitors to return to G1, possibly to achieve balanced 
asymmetric cell division. In agreement with this, the number of HPCs appear to be decreased 
also compared to pre-treatment levels, and the fewer HPCs that remain following inhibition of 
CDK1 are counterintuitively enriched in G1, and possibly represent cells that did not enter the 
cell cycle and were not affected by the treatment. Accordingly, and as discussed above, the 
inhibition of CDK4/6 causes enrichment of these cells in G1, thus preserving the cluster size, 
although impairing their multilineage differentiation potential. Together, these results suggest 
that HPCs differentiate upon cell cycle entry, likely following a default differentiation 
programme towards the erythroid compartment, and that the population is exhausted when G1 
re-entry is prevented. Thus, CDK1 activity appears to have a key role during EHT, being 
potentially essential for both the specification of multipotent HPCs and the prevention of their 
uncontrolled differentiation leading to exhaustion (Figure 5.14C). Further experiments 
including the isolation and single cell differentiation of the HPCs upon treatment will be able 
to confirm if this model is correct. Of note, the cell cycle state of the erythroid progenitors does 
not seem to be affected by the inhibition of CDK1. This regulator was previously reported to be 
absolutely fundamental during mouse embryonic development, with other CDKs not able to 
drive proliferation beyond the blastocyst stage (Santamaría et al., 2007b). However, other CDKs 
can replace CDK1 in the adult, as shown by the use of conditional knockout mice revealing that 
liver regeneration is not impaired by loss of CDK1 (Diril et al., 2012). Thus, a similar functional 
redundancy with other CDKs replacing CDK1 might take place in the erythroid cluster, 




Figure 5.14 Proposed model for the role of CDK4/6 and CDK1 during EHT. (A) Endothelial cells 
transitioning to the haematopoietic fate are associated with cell cycle entry. This results in the specification of 
HPCs, a transitory population which in culture quickly commits to produce highly proliferative erythroid 
progenitors. (B) CDK4/6 is necessary for both specification and further differentiation of HPCs. Its inhibition 
results in the endothelial cells blocked in G1 and not undergoing EHT, and with the already generated HPCs 
also blocked in G1 and unable to further differentiate. The consequence is an enrichment in endothelial cells, 
a decrease in erythroid progenitors, and the preservation of the HPC population associated with depletion of 
their multilineage potential, possibly skewed towards the myeloid lineage. (C) CDK1 is necessary for HPC 
specification and balanced differentiation. Its inhibition blocks EHT, while the commitment of already 
generated HPCs is not blocked, resulting in their further differentiation and quick exhaustion. This leads to 




Functional redundancy might also explain the nonessential requirement observed for 
CDK2 during EHT. It was previously shown that CDK2 knockout mice are viable, despite germ 
cell development in these animals being affected (Berthet et al., 2003). Similarly, CDK2 does 
not appear to be required for endothelial cells to undergo EHT, possibly replaced by other 
CDKs, and its inhibition causes in erythroid cells only a very limited enrichment in S phase. Of 
note, the treatment instead increases both S and G2/M phases in the HPC cluster, suggesting 
that in this particular population both CDK2 and CDK1 might be affected by the inhibitor. This 
might explain the little increase in the number of CFU-E colonies generated in the CFU assay, 
in agreement with what discussed for the role of CDK1 and with previous studies suggesting 
that the erythroid differentiation programme is reinforced during the S phase (Pop et al., 2010). 
However, this treatment does not seem to block CDK1 very efficiently, while CDK2 might be 
functionally replaced by other CDKs, overall explaining the limited effect observed. 
Additionally, the analysis of genes differentially expressed across different conditions 
shows that each treatment causes, to a different extent, upregulation of erythroid genes in the 
HPC cluster. This suggests that perturbations of the cell cycle progression might interfere with 
the maintenance of an undifferentiated state and that the erythroid fate constitutes a default 
differentiation programme in this culture conditions. In this context, despite the transcriptional 
upregulation, CDK4/6 activation and G1/S transition appear to be necessary for the fulfilment 
of this programme, while CDK1 and G1 re-entry seems to be essential for the prevention of 
uncontrolled differentiation. An additional role for CDK1 in HPCs might also involve a 
crosstalk with the MAPK signalling and the cellular response to stress conditions, as shown by 
the upregulation of MALAT1, NEAT1 and TXNIP (Li et al., 2009; Liu et al., 2014; Fuschi et al., 
2017; Tian et al., 2017). This will need to be further explored, for example with the use of 
agonists and antagonists for the modulation of the MAPK pathway. Overall, a balanced control 
of the cell cycle progression appears to be fundamental for the HPC population. 
Finally, the mesenchymal cluster does not appear to be affected by perturbations of the 
cell cycle machinery, despite changes in its cell cycle profile. This would suggest that the 
production of mesenchymal cells occurs without cell cycle progression, and therefore that EHT 
and EndoMT are controlled through very different mechanisms, with the cell cycle machinery 
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regulating the generation of haematopoietic, but not mesenchymal, cells. Alternatively, it is also 
possible that EndoMT takes place earlier than EHT and is mostly complete at the time examined 
for this study. Indeed, my results reveal that the mesenchymal cluster remains constant during 
the interval analysed, with only a slight increase from EHT D3 to EHT D5 (Figure 3.8). In 
addition, a deeper analysis of the endothelial population showed that cells engaged in EndoMT 
have already started upregulating mesenchymal genes, compared to the fewer cells engaged in 
EHT in which haematopoietic genes have not yet been induced, despite downregulation of 
endothelial markers (Figure 4.6) This might indicate that EndoMT takes place earlier than EHT 
and is already in an advanced state at the time considered for my experiments. Therefore, my 
results would only show that the cell cycle does not play a role in mesenchymal cell homeostasis. 
If this is the case, further experiments focusing on earlier time points will be necessary to study 
the role of cell cycle regulation in EndoMT leading to mesenchymal cell generation. Of note, 
EndoMT has been previously shown to be induced by TGFβ signalling, leading to tissue fibrosis 
(Wermuth et al., 2016). TGFβ is also known to cause cell cycle arrest by inducing the expression 
of regulators such as p21 and the inactivation of G1/S cyclin-CDK complexes (Datto et al., 1995; 
Hocevar and Howe, 1998; Yoo et al., 1999). Therefore, it is possible that EndoMT does not 
require cell cycle progression and that cell cycle arrest promotes the generation of mesenchymal 
cells. Thus, the in vitro model used for this dissertation could allow studying the production of 
these cells and potentially reveal novel mechanisms controlling EndoMT, relevant for 
development and disease. My results suggest that EndoMT and EHT might represent two 
alternative cell fate choices undertaken by endothelial cells during development. Intriguingly, 
an early cell cycle state modulation, possibly regulated by TGFβ, might control this choice, with 
cell cycle arrest promoting EndoMT and cell cycle progression essential for EHT. Further 
experiments focusing on earlier endothelial cells will be necessary to test this hypothesis. 
Importantly, the gating strategy developed in this study will allow to quickly monitor any effect 
on the balance between EHT and EndoMT. 
In conclusion, cell cycle entry and progression, associated with the timely activation of 
CDK4/6 during the G1 phase and CDK1 in G2/M, appear to be essential for endothelial cells to 
undergo EHT and generate HPCs. Once generated, these progenitors engage cell cycle more 
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actively, and quickly differentiate, with the activity of CDK4/6 necessary for cell cycle 
progression and differentiation, and the activity of CDK1 important for G1 re-entry to maintain 
the HPC state and avoid uncontrolled commitment. Overall, a complex interplay between the 
molecular machineries controlling cell cycle progression and cell fate decision appears to be 
fundamental during EHT, and potentially plays additional roles in processes such as EndoMT 
in determining endothelial cell plasticity and differentiation dynamics.  
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5.6 Annexe: Gene Ontology analyses for differentially 
expressed genes 
 
Table 5.1 GO terms for CDK4/6i downregulated genes in the endothelial cluster.  
Endothelial cluster | CDK4/6i downregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
ribosomal small subunit export from nucleus (GO:0000056) 0.00698 0.05914 -4.17 20.7 
mitochondrial ATP synthesis coupled proton transport 
(GO:0042776) 
0.02178 0.07542 -4.96 18.99 
mitochondrial electron transport, NADH to ubiquinone 
(GO:0006120) 
0.001 0.04224 -2.73 18.88 
mitochondrial ATP synthesis coupled electron transport 
(GO:0042775) 
8.3E-05 0.006288 -1.9 17.87 
viral process (GO:0016032) 6.1E-05 0.006288 -1.7 16.45 
response to type I interferon (GO:0034340) 0.00797 0.05914 -2.97 14.36 
positive regulation of apoptotic cell clearance (GO:2000427) 0.00797 0.05914 -2.78 13.42 
ribosomal subunit export from nucleus (GO:0000054) 0.01293 0.06483 -3.08 13.38 
regulation of glial cell apoptotic process (GO:0034350) 0.00698 0.05914 -2.65 13.17 
positive regulation of nitric-oxide synthase biosynthetic 
process (GO:0051770) 
















Table 5.2 GO terms for CDK4/6i downregulated genes in the mesenchymal cluster. 
Mesenchymal cluster | CDK4/6i downregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
mitochondrial electron transport, NADH to ubiquinone 
(GO:0006120) 
0.000009682 0.000568 -2.74 31.58 
mitochondrial ATP synthesis coupled electron transport 
(GO:0042775) 
9.31E-07 0.0001222 -1.9 26.42 
ribosomal small subunit export from nucleus 
(GO:0000056) 
0.006284 0.04096 -4.16 21.09 
mitochondrial ATP synthesis coupled proton transport 
(GO:0042776) 
0.01962 0.05571 -4.94 19.43 
respiratory electron transport chain (GO:0022904) 0.000001389 0.0001222 -1.36 18.33 
mitochondrial respiratory chain complex I biogenesis 
(GO:0097031) 
0.00002582 0.0007574 -1.58 16.68 
NADH dehydrogenase complex assembly (GO:0010257) 0.00002582 0.0007574 -1.57 16.64 
mitochondrial respiratory chain complex assembly 
(GO:0033108) 
0.00008825 0.002219 -1.78 16.58 
V(D)J recombination (GO:0033151) 0.007179 0.04211 -3.26 16.12 
mitochondrial respiratory chain complex I assembly 
(GO:0032981) 
0.00002582 0.0007574 -1.41 14.9 
 
Table 5.3 GO terms for CDK4/6i downregulated genes in the erythroid cluster. 
Erythroid cluster | CDK4/6i downregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
mitochondrial ATP synthesis coupled electron transport 
(GO:0042775) 
2.92E-10 1.25E-07 -1.9 41.77 
mitochondrial electron transport, NADH to ubiquinone 
(GO:0006120) 
0.000002073 0.0002228 -2.73 35.77 
V(D)J recombination (GO:0033151) 0.000103 0.00492 -3.28 30.13 
respiratory electron transport chain (GO:0022904) 5.92E-10 1.27E-07 -1.36 28.88 
mitochondrial respiratory chain complex assembly 
(GO:0033108) 
0.000001286 0.0001843 -1.78 24.16 
DNA topological change (GO:0006265) 0.0001651 0.007099 -2.47 21.54 
DNA geometric change (GO:0032392) 0.00001531 0.0008227 -1.87 20.72 
DNA ligation involved in DNA repair (GO:0051103) 0.0002851 0.009431 -2.5 20.44 
mitochondrial respiratory chain complex I biogenesis 
(GO:0097031) 
0.000007671 0.0004712 -1.58 18.59 
NADH dehydrogenase complex assembly (GO:0010257) 0.000007671 0.0004712 -1.57 18.54 
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Table 5.4 GO terms for CDK4/6i upregulated genes in the erythroid cluster. 
Erythroid cluster | CDK4/6i upregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
membrane raft assembly (GO:0001765) 0.004193 0.05535 -3.89 21.31 
regulation of viral entry into host cell (GO:0046596) 0.0001149 0.02343 -1.89 17.14 
regulation of muscle system process (GO:0090257) 0.005985 0.05535 -2.94 15.05 
membrane raft organization (GO:0031579) 0.006582 0.05535 -2.96 14.86 
genetic imprinting (GO:0071514) 0.005388 0.05535 -2.57 13.41 
response to muscle stretch (GO:0035994) 0.005985 0.05535 -2.57 13.14 
regulation of glycogen (starch) synthase activity 
(GO:2000465) 
0.004791 0.05535 -2.44 13.05 
negative regulation of DNA metabolic process 
(GO:0051053) 
0.0003079 0.0314 -1.52 12.28 
regulation of apoptotic process (GO:0042981) 0.001047 0.05535 -1.79 12.27 
positive regulation of G1/S transition of mitotic cell cycle 
(GO:1900087) 
0.01016 0.05535 -2.66 12.22 
 
Table 5.5 GO terms for CDK4/6i downregulated genes in the HPC cluster. 
HPC cluster | CDK4/6i downregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
mitochondrial electron transport, NADH to ubiquinone 
(GO:0006120) 
2.75E-07 0.00001807 -2.73 41.3 
mitochondrial ATP synthesis coupled electron transport 
(GO:0042775) 
6.70E-10 1.62E-07 -1.9 40.19 
DNA topological change (GO:0006265) 1.81E-07 0.00001588 -2.48 38.54 
V(D)J recombination (GO:0033151) 0.00003847 0.0008432 -3.28 33.34 
respiratory electron transport chain (GO:0022904) 1.23E-09 1.62E-07 -1.36 27.89 
DNA ligation (GO:0006266) 0.000001453 0.00004245 -2.07 27.79 
apoptotic nuclear changes (GO:0030262) 0.000003022 0.00007949 -1.91 24.29 
DNA ligation involved in DNA repair (GO:0051103) 0.0001068 0.00216 -2.5 22.89 
mitochondrial respiratory chain complex I biogenesis 
(GO:0097031) 
0.000001028 0.00003862 -1.58 21.76 
NADH dehydrogenase complex assembly (GO:0010257) 0.000001028 0.00003862 -1.57 21.7 
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Table 5.6 GO terms for CDK4/6i upregulated genes in the HPC cluster. 
HPC cluster | CDK4/6i upregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
regulated exocytosis (GO:0045055) 0.00002208 0.001921 -2.3 24.7 
membrane raft assembly (GO:0001765) 0.002797 0.03577 -3.89 22.88 
defense response to protozoan (GO:0042832) 0.003595 0.03577 -2.98 16.76 
platelet degranulation (GO:0002576) 0.00001305 0.001921 -1.44 16.15 
membrane raft organization (GO:0031579) 0.004392 0.03577 -2.96 16.05 
regulation of MHC class II biosynthetic process 
(GO:0045346) 
0.003595 0.03577 -2.73 15.38 
positive regulation of cAMP-mediated signaling 
(GO:0043950) 
0.003595 0.03577 -2.7 15.2 
positive regulation of macrophage differentiation 
(GO:0045651) 
0.003595 0.03577 -2.59 14.56 
genetic imprinting (GO:0071514) 0.003595 0.03577 -2.57 14.45 
regulation of glycogen (starch) synthase activity 
(GO:2000465) 
0.003196 0.03577 -2.44 14.04 
 
Table 5.7 GO terms for CDK2/1i upregulated genes in the HPC cluster. 
HPC cluster | CDK2/1i upregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
oxygen homeostasis (GO:0032364) 0.002448 0.01284 -4.71 28.29 
gas homeostasis (GO:0033483) 0.002797 0.01284 -4.18 24.56 
positive regulation of neutrophil chemotaxis (GO:0090023) 0.00003138 0.0008552 -2.2 22.84 
positive regulation of granulocyte chemotaxis 
(GO:0071624) 
0.0000367 0.0008552 -1.97 20.14 
positive regulation of neutrophil migration (GO:1902624) 0.00003399 0.0008552 -1.95 20.01 
regulation of leukocyte chemotaxis (GO:0002688) 0.00004859 0.0008552 -2 19.83 
oxygen transport (GO:0015671) 0.002797 0.01284 -3.32 19.53 
regulation of neutrophil chemotaxis (GO:0090022) 0.00004546 0.0008552 -1.77 17.74 
defense response to protozoan (GO:0042832) 0.003146 0.01284 -2.97 17.11 
positive regulation of leukocyte migration (GO:0002687) 0.00006214 0.0009113 -1.65 16.01 
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Table 5.8 GO terms for CDK1i downregulated genes in the endothelial cluster. 
Endothelial cluster | CDK1i downregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
positive regulation of nitric-oxide synthase biosynthetic 
process (GO:0051770) 
0.0000383 0.01255 -2.82 28.65 
regulation of nitric-oxide synthase biosynthetic process 
(GO:0051769) 
0.00006628 0.01255 -2.58 24.83 
ribosomal small subunit export from nucleus (GO:0000056) 0.006632 0.05774 -4.15 20.81 
mitochondrial ATP synthesis coupled proton transport 
(GO:0042776) 
0.0207 0.05998 -4.86 18.84 
positive regulation of activated T cell proliferation 
(GO:0042104) 
0.0001608 0.01267 -2.15 18.76 
positive regulation of cell migration by vascular endothelial 
growth factor signaling pathway (GO:0038089) 
0.007576 0.05774 -3.47 16.95 
regulation of positive chemotaxis (GO:0050926) 0.008519 0.05774 -3.55 16.93 
protein kinase B signaling (GO:0043491) 0.0005284 0.02313 -1.97 14.87 
response to type I interferon (GO:0034340) 0.007576 0.05774 -2.95 14.4 
positive regulation of apoptotic cell clearance (GO:2000427) 0.007576 0.05774 -2.76 13.47 
 
Table 5.9 GO terms for CDK1i upregulated genes in the endothelial cluster. 
Endothelial cluster | CDK1i upregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
cytoskeleton-dependent intracellular transport 
(GO:0030705) 
0.00007845 0.006058 -2.09 19.73 
regulation of transcription from RNA polymerase II 
promoter in response to oxidative stress (GO:0043619) 
0.004492 0.04395 -3.6 19.45 
cell cycle G2/M phase transition (GO:0044839) 0.00002973 0.005055 -1.82 18.98 
V(D)J recombination (GO:0033151) 0.003994 0.04395 -3.27 18.05 
regulation of mitotic cell cycle phase transition 
(GO:1901990) 
0.00008908 0.006058 -1.91 17.85 
outer mitochondrial membrane organization (GO:0007008) 0.003994 0.04395 -3.23 17.84 
regulation of G2/M transition of mitotic cell cycle 
(GO:0010389) 
0.00004774 0.005411 -1.77 17.61 
negative regulation of translation in response to stress 
(GO:0032055) 
0.003495 0.04395 -3.09 17.48 
regulation of translational initiation in response to stress 
(GO:0043558) 
0.003495 0.04395 -2.84 16.07 
regulation of nuclease activity (GO:0032069) 0.003495 0.04395 -2.83 15.99 
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Table 5.10 GO terms for CDK1i downregulated genes in the mesenchymal cluster. 
Mesenchymal cluster | CDK1i downregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
ribosomal small subunit export from nucleus (GO:0000056) 0.005587 0.0459 -4.17 21.63 
mitochondrial electron transport, NADH to ubiquinone 
(GO:0006120) 
0.0006352 0.0305 -2.74 20.14 
mitochondrial ATP synthesis coupled proton transport 
(GO:0042776) 
0.01746 0.05732 -4.96 20.08 
mitochondrial ATP synthesis coupled electron transport 
(GO:0042775) 
0.00004128 0.004197 -1.9 19.21 
bleb assembly (GO:0032060) 0.006383 0.0459 -3 15.15 
ribosomal subunit export from nucleus (GO:0000054) 0.01035 0.05579 -3.08 14.08 
respiratory electron transport chain (GO:0022904) 0.00005559 0.004197 -1.36 13.32 
genetic imprinting (GO:0071514) 0.007178 0.04927 -2.56 12.64 
regulation of glycogen (starch) synthase activity 
(GO:2000465) 
0.006383 0.0459 -2.43 12.27 
protein targeting to ER (GO:0045047) 0.002727 0.03956 -2.08 12.26 
 
Table 5.11 GO terms for CDK1i downregulated genes in the erythroid cluster. 
Erythroid cluster | CDK1i downregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
regulation of protein targeting (GO:1903533) 0.005936 0.03332 -4.26 21.86 
ribosomal small subunit export from nucleus (GO:0000056) 0.005936 0.03332 -4.17 21.37 
mitochondrial electron transport, NADH to ubiquinone 
(GO:0006120) 
0.0007188 0.02581 -2.74 19.8 
mitochondrial ATP synthesis coupled proton transport 
(GO:0042776) 
0.01854 0.04191 -4.96 19.77 
mitochondrial ATP synthesis coupled electron transport 
(GO:0042775) 
0.00004997 0.003801 -1.9 18.84 
folic acid-containing compound biosynthetic process 
(GO:0009396) 
0.005936 0.03332 -3.45 17.69 
oxygen transport (GO:0015671) 0.006781 0.03332 -3.32 16.57 
positive regulation of autophagy of mitochondrion 
(GO:1903599) 
0.006781 0.03332 -3 15 
ribosomal subunit export from nucleus (GO:0000054) 0.011 0.04056 -3.08 13.89 
pteridine-containing compound biosynthetic process 
(GO:0042559) 
0.006781 0.03332 -2.68 13.41 
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Table 5.12 GO terms for CDK1i upregulated genes in the erythroid cluster. 
Erythroid cluster | CDK1i upregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
negative regulation of membrane protein ectodomain 
proteolysis (GO:0051045) 
0.003196 0.04232 -2.66 15.26 
negative regulation of reproductive process (GO:2000242) 0.004392 0.04232 -2.54 13.81 
sequestering of actin monomers (GO:0042989) 0.004392 0.04232 -2.43 13.17 
regulation of integrin-mediated signaling pathway 
(GO:2001044) 
0.004791 0.04232 -2.3 12.27 
regulation of trophoblast cell migration (GO:1901163) 0.004791 0.04232 -2.24 11.96 
negative regulation of DNA replication (GO:0008156) 0.006781 0.04303 -2.2 10.96 
positive regulation of viral entry into host cell (GO:0046598) 0.003595 0.04232 -1.85 10.44 
transition metal ion homeostasis (GO:0055076) 0.009958 0.04303 -2.23 10.26 
cellular iron ion homeostasis (GO:0006879) 0.02258 0.0497 -2.61 9.91 
negative regulation of actin filament polymerization 
(GO:0030837) 
0.009165 0.04303 -1.83 8.57 
 
Table 5.13 GO terms for CDK1i downregulated genes in the HPC cluster. 
HPC cluster | CDK1i downregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
mitochondrial ATP synthesis coupled electron transport 
(GO:0042775) 
8.30E-11 4.67E-08 -1.9 44.16 
mitochondrial electron transport, NADH to ubiquinone 
(GO:0006120) 
0.000001458 0.0001368 -2.73 36.68 
respiratory electron transport chain (GO:0022904) 2.06E-10 5.79E-08 -1.36 30.32 
mitochondrial ATP synthesis coupled proton transport 
(GO:0042776) 
0.003724 0.03913 -4.95 27.71 
mitochondrial electron transport, cytochrome c to oxygen 
(GO:0006123) 
0.0001003 0.002822 -2.57 23.62 
mRNA splicing, via spliceosome (GO:0000398) 0.000001398 0.0001368 -1.75 23.54 
histone mRNA metabolic process (GO:0008334) 0.0001484 0.003632 -2.29 20.16 
gene expression (GO:0010467) 1.29E-07 0.00002419 -1.26 19.94 
establishment of protein localization to mitochondrion 
(GO:0072655) 
0.00005491 0.001932 -2.02 19.86 
nucleocytoplasmic transport (GO:0006913) 0.00004293 0.001859 -1.95 19.59 
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Table 5.14 GO terms for CDK1i upregulated genes in the HPC cluster. 
HPC cluster | CDK1i upregulated genes | GO Biological Process 
Name p-value adjusted p-value z score combined score 
cellular iron ion homeostasis (GO:0006879) 0.000003262 0.0008498 -2.65 33.52 
iron ion homeostasis (GO:0055072) 9.99E-08 0.00005206 -1.57 25.36 
oxygen homeostasis (GO:0032364) 0.01253 0.09524 -4.65 20.36 
positive regulation of cell cycle arrest (GO:0071158) 0.00001468 0.001912 -1.71 19.01 
ribosomal small subunit export from nucleus 
(GO:0000056) 
0.01253 0.09524 -4.12 18.06 
gas homeostasis (GO:0033483) 0.01431 0.09524 -4.11 17.47 
neutrophil degranulation (GO:0043312) 0.0001957 0.01014 -2.01 17.14 
cellular transition metal ion homeostasis (GO:0046916) 0.00002402 0.002503 -1.59 16.88 
neutrophil mediated immunity (GO:0002446) 0.000214 0.01014 -1.93 16.31 
DNA damage response, signal transduction by p53 class 
mediator (GO:0030330) 




















6 FUTURE PERSPECTIVES AND CONCLUSIONS 
 
6.1 Future directions 
 
The results discussed in this dissertation contributed to expand our knowledge about the 
specification of haematopoietic progenitors taking place during development. At the same time, 
they also paved the way for future experiments for the further exploration of these mechanisms 
and to new lines of investigation extending beyond haematopoietic development. 
 
6.2 Molecular networks linking cell cycle and cell fate decision 
 
My results suggest that the cell cycle progression could be a requirement for EHT, and I 
have proposed distinct roles for CDK4/6 and CDK1 during haematopoietic specification and 
differentiation. However, the molecular network linking cell fate decision and cell cycle 
regulation still remains to be elucidated.  
As previously discussed (Chapter 5.5), CDK4/6 might bind to RUNX1 and participate in 
the regulation of its transcriptional activity. Of note, cyclin D3 was also suggested to have a 
similar role (Peterson et al., 2005). This would be in agreement with my results showing a cell 
type-specific expression for distinct cyclin D isoforms, with cyclin D1/D2 expressed in 
endothelial and mesenchymal cells and cyclin D3 preferentially expressed in the haematopoietic 
compartment (Figure 4.3). This potentially suggests that RUNX1 activity might be cell cycle 
regulated by its interaction in the G1 phase with cyclin D3 and CDK6. However, RUNX1 is also 
part of a complex transcriptional network involving other key players such as GATA2 and 
TAL1 (Chapter 1.7.5). Therefore, if the cell cycle dependent regulation of RUNX1 was 
confirmed to take place during EHT, this could possibly extend to other factors controlling the 
haematopoietic transcriptional programme. In this regards, the in vitro model presented in this 
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dissertation offers the unprecedented opportunity to further explore these hypotheses and 
potentially identify effector proteins interacting with key cell cycle regulators. For that, it will 
be interesting to test the interaction of these and other cell cycle regulators with key 
haematopoietic transcription factors controlling EHT, for example with the use of techniques 
such as the proximity ligation assay. Furthermore, the combination of these experiments with 
the FUCCI reporter system might potentially confirm if this interaction takes place during 
specific cell cycle phases. 
On the other hand, the analysis of genes differentially expressed upon inhibition of CDK1 
revealed a potential role for this factor in the regulation of the cellular response to oxidative 
stress, suggested to be regulated by MALAT1, NEAT1 and TXNIP and mediated by the MAPK 
signalling pathway (Li et al., 2009; Liu et al., 2014; Fuschi et al., 2017; Tian et al., 2017). Of note, 
cyclin B1-CDK1 was previously shown to localise to the mitochondrial matrix and to 
phosphorylate proteins including components of the respiratory chain, thus increasing 
mitochondrial respiration (Wang et al., 2014b). These findings suggest that CDK1 could 
potentially modulate the oxidative metabolism and at the same time a MAPK-mediated 
response to oxidative stress. Further experiments will allow exploring the role of this 
mechanism during haematopoietic specification and differentiation, for example performing a 
metabolomics analysis upon CDK1 inhibition or using agonists and antagonist of the MAPK 
signalling to study the role of this pathway during distinct stages of EHT. 
Overall, these experiments will allow to further elucidate the molecular network linking 
cell cycle state and haematopoietic specification. 
 
6.3 Manipulation of the cell cycle machinery for the improved 
production of haematopoietic cells 
 
The work presented in this dissertation shows that the haemogenic endothelial cells seem 
to be in a quiescent state, characterised by the expression of cell cycle inhibitors of the Rb and 
CIP/KIP families, and as previously hypothesised (Chapter 4.5), the removal of these molecular 
147 
breaks might be the first necessary event for the onset of EHT. Thus, inhibiting the activity of 
these cell cycle inhibitors might potentially induce a larger fraction of endothelial cells to 
transition towards the haematopoietic fate. This could be done with the use of small molecule 
inhibitors or knockdown mediated by short hairpin RNAs. Based on my results, I anticipate 
that the inhibition of these cell cycle inhibitors might increase the number of endothelial cells 
entering and progressing through the cell cycle, and consequently the number of cells 
undergoing EHT. This approach might be used to screen multiple regulators and identify those 
with the higher impact on differentiation. Furthermore, multiple signalling pathways might be 
tested for their capacity to control these cell cycle regulators and promote cell cycle entry and 
EHT. Overall this approach might allow the identification of signalling pathways controlling 
cell cycle and able to improve the efficiency of differentiation.  
On the other hand, my results suggest that uncontrolled cell cycle progression would lead 
to exhaustion of the HPC population. Thus, an accurate control over these mechanisms would 
be likely required, possibly involving a sequential activation and inhibition of these signalling 
pathways to achieve an initial cell cycle activation to promote EHT and a subsequent cell cycle 
exit to preserve the HPC population. Indeed, a similar regulation appears to take place in vivo, 
when early HSPCs are generated in the AGM and migrate to the foetal liver where they are 
gradually induced to exit the cell cycle (Hur et al., 2016).  
Of note, an important candidate signal would be TGFβ, known to induce the expression 
of cell cycle inhibitors such as p21 and promote cell cycle arrest (Datto et al., 1995; Hocevar and 
Howe, 1998; Yoo et al., 1999). In agreement with my hypothesis, TGFβ signalling was reported 
to inhibit EHT (Vargel et al., 2016). Indeed, based on my results I speculate that an initial 
inhibition of the pathway might be necessary for cell cycle activation and induction of EHT, 





6.4 Further characterisation and maturation of multipotent 
HPCs 
 
The simple but effective sorting strategy developed in this study allows the isolation of 
the first population of haematopoietic progenitors generated in vitro. Further characterization 
of this population will be necessary to determine if these cells are indeed multipotent or if they 
represent instead heterogeneous progenitors capable of multilineage differentiation only at the 
population level. For that, single cell differentiation experiments will be essential. The isolation 
of this population will also be necessary to confirm the hypothesised roles of CDK4/6 and CDK1 
in differentiation. Furthermore, this will allow to further expand their characterisation and to 
potentially identify signalling pathways that control their commitment or self-renewal.  
Of note, our group has developed protocols for the differentiation of hPSCs towards liver 
cell types such as hepatocytes or cholangiocytes, and systems for their co-culture in 3D 
environments based on Matrigel or collagen. Importantly, these cells are characterised by a 
foetal phenotype, and appear to increase their maturation upon 3D co-culture (data not 
published). Therefore, a novel line of investigation would be represented by the isolation of 
HPCs generated upon EHT for their 3D co-culture with in vitro differentiated hepatic cell types, 
in an attempt to model HSPC migration to the foetal liver taking place during development 
upon their generation in the AGM, and therefore recapitulate their developmental niche and 
possibly induce maturation.  
 
6.5 Regulation of endothelial-to-mesenchymal transition 
 
Finally, my results revealed an additional population generated in this in vitro system, 
constituted by mesenchymal cells possibly generated from the endothelium through EndoMT. 
This population does not appear to be affected by perturbations of the cell cycle, although it is 
possible that EndoMT is a process temporally preceding EHT and that the treatments used in 
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this study need to be anticipated to produce an effect. Indeed, early cell cycle arrest might 
promote mesenchymal differentiation, which would be consistent with the reported role of 
TGFβ in both promoting EndoMT and inducing cell cycle arrest, as previously discussed 
(Chapter 5.5), and in agreement with its inhibitory effect on EHT (Vargel et al., 2016). Thus, 
the in vitro differentiation here characterised could possibly be adapted to model this additional 
process, relevant for both development and disease, and it appears that EndoMT and EHT 
might represent two alternative cell fate choices. Importantly, using the same gating strategy 
developed in this work for the isolation of HPCs, it could be possible to isolate the mesenchymal 
population for further characterisation. This would allow to functionally test these cells for their 
ability to differentiate, for example towards the generation of cell types like osteoblast cells. 
Ultimately, this would open multiple lines of investigation, involving the characterisation of the 
mesenchymal population and the identification of novel molecular mechanisms important for 




This dissertation contributes to elucidate molecular mechanisms driving a complex 
developmental event such as the endothelial-to-haematopoietic transition, and to the 
understanding of dynamics and mechanisms driving early haematopoietic specification and 
commitment. The use of human pluripotent stem cells and the optimisation of an in vitro 
differentiation system to model human haematopoietic ontogeny, in combination with high-
throughput single cell RNA sequencing, allowed me to draw an accurate picture of a 
developmental stage which is otherwise difficult to access in human in vivo. This approach 
allowed me to explore the complexity of this heterogeneous system and to identify and 
characterise with unprecedented detail the populations involved. I was able to determine that 
such populations are characterised by distinct and specific cell cycle states, which I suggested to 
be determinant in the capability of the endothelial cells to undergo the transition towards the 
haematopoietic fate. Indeed, cell cycle progression appears to have an important role in this 
process, and I hypothesise that this might be due to the activation of transcriptional 
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programmes which are cell cycle regulated, possibly controlled by the timely activation of CDK 
regulators at specific cell cycle phases. I have indeed proposed a model for the role of CDK4/6 
and CDK1 in the specification of haematopoietic progenitors and their further differentiation, 
although the specific molecular network modulated by these regulators still needs to be 
explored. For that, the isolation of the first population capable of multilineage differentiation 
will substantially increase our understanding of these mechanisms.  
Collectively, the results presented in this dissertation contribute to the knowledge 
currently available in the field, and pave the way to future studies and exciting developments in 
regenerative medicine, such as the in vitro generation of cells capable of self-renewal and 
multilineage engraftment or the design of more effective culture conditions for the ex vivo 



























7 MATERIAL AND METHODS 
 
7.1 Culture of hPSCs 
 
The hIPSC lines A1AT-RR (Yusa et al., 2011) and FSPS13B were maintained as previously 
described (Chen et al., 2011b) on plates coated with 10 μg/ml Vitronectin (Stem Cell 
Technologies) and cultured in E6 media supplemented with 2 ng/ml TGFβ (R&D) and 25 ng/ml 
FGF2 (from Dr. Marko Hynoven, Department of Biochemistry, University of Cambridge). Cells 
were maintained at 37 °C and 5% CO2, and passaged every 5-6 days by dissociation with 0.5 
mM EDTA (ThermoFisher Scientific). For coating plates, 10 μg/ml Vitronectin in PBS 
(ThermoFisher Scientific) was applied for at least 1 hour at room temperature. 
 
7.2 Haematopoietic differentiation 
 
Differentiation was performed at 5% O2 by adapting a protocol previously described 
(Ditadi et al., 2015). Briefly, a serum-free differentiation (SFD) medium was used, consisting of 
75% Iscove's modified Dulbecco's medium (ThermoFisher Scientific) and 25% Ham's F12 
medium (ThermoFisher Scientific) supplemented with 1% N2 (ThermoFisher Scientific), 0.5% 
B27 (ThermoFisher Scientific), 0.05% BSA (Sigma-Aldrich), 1 mM ascorbic acid (2-phospho-
L-ascorbic acid trisodium salt, Sigma-Aldrich), 4.5x10-4 monothioglycerol (Sigma-Aldrich), 2 
mM L-glutamine (ThermoFisher Scientific),  150 μg/ml transferrin (Sigma-Aldrich) and 10 
ng/ml penicillin/streptomycin (ThermoFisher Scientific). Undifferentiated cells were 
dissociated using 0.5 mM EDTA and small aggregates were resuspended in SFD medium 
supplemented with 10 ng/ml BMP4 (R&D) and cultured as EBs on non-treated plates (Starlab). 
After 24 hours, an equivalent volume of SFD was added directly on top to not perturb the small 
EBs, supplemented with final concentrations of 10 ng/ml BMP4 and 5 ng/ml FGF2. At day 2, 
developing EBs were collected and washed. For this, they were centrifuged 3 minutes at 100 g, 
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gently resuspended in SFD supplemented with 10 ng/ml BMP4, 5 ng/ml FGF2 and 3 μM 
CHIR99021 (Tocris), and seeded back on the plate. After 24 hours, EBs were again collected 
and washed, this time by centrifuging at 300 g for 3 minutes, and resuspended in StemPro-34 
SFM (ThermoFisher Scientific) supplemented with 1 mM ascorbic acid, 4.5x10-4 
monothioglycerol, 2 mM L-glutamine, 150 μg/ml transferrin, 10 ng/ml penicillin/streptomycin 
(from now on referred to as complete SP34) containing 5 ng/ml FGF2, 15 ng/ml VEGF 
(Peprotech), 10 ng/ml IL-6 (R&D) and 5 ng/ml IL-11 (R&D), and cultured for 48 hours. At day 
5, EBs were again collected, washed and resuspended in complete SP34 with 5 ng/ml FGF2, 15 
ng/ml VEGF, 10 ng/ml IL-6, 5 ng/ml IL-11, 50 ng/ml SCF (R&D), 5 ng/ml IGF-1 (R&D), 2 
U/ml EPO (R&D) and cultured until day 8. At this stage, EBs were collected and prepared for 
sorting. For this, they were incubated for 20 minutes at 37 °C with collagenase solution, 
composed of Advanced DMEM/F12 (ThermoFisher Scientific), 20% KSR (ThermoFisher 
Scientific), 1% L-glutamine and 1 mg/ml collagenase IV (ThermoFisher Scientific), followed by 
3 minutes incubation with TrypLE (ThermoFisher Scientific). Single cells were then stained for 
flow cytometry and the CD34+/CD43- fraction was sorted and used for the second stage of 
differentiation. For this, the population was resuspended at a density of 106 cells/ml in complete 
SP34 with 10 ng/ml BMP4, 5 ng/ml FGF2, 5 ng/ml VEGF, 10 ng/ml IL-6, 5 ng/ml IL-11, 100 
ng/ml SCF, 25 ng/ml IGF-1, 30 ng/ml TPO (Peprotech), 30 ng/ml IL-3 (Peprotech), 10 ng/ml 
Flt3-L (R&D), 20 ng/ml SHH (R&D), 10 ng/ml angiotensin II (Sigma-Aldritch) and 100 μM 
losartan potassium (R&D). Cells were transferred to a non-treated round-bottom 96 well plate 
(Corning), 200 μl/well (corresponding to 2x105 cells/well), centrifuged 3 minutes at 300 g, and 
incubated overnight to allow the cells to re-aggregate. On the following day, marking EHT D1, 
the small aggregates were plated on Matrigel (Corning). For this, they were gently transferred 
to thin-layer Matrigel-coated wells, with a density of 2x105 cells/well in a 24 well plate, and 
cultured for additional 2-4 days using the same media, replaced every 2 days. For coating plates, 
Matrigel was diluted into cold medium with a concentration of 35 μg/cm2 of surface to be 
coated, and applied overnight at 37 °C. For treatments with cell cycle inhibitors, 0.1 μg/mL 
Nocodazole (Sigma-Aldrich), 1 μM PD0332991 (Tocris), 4 μM Roscovitine (Sigma-Aldrich), 
10 μM RO3306 (Sigma-Aldrich) or 0.1% DMSO were added at EHT D3 for 48 hours.  
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7.3 Isolation of CD34+ peripheral blood mononuclear cells 
 
Under sterile conditions, peripheral blood was diluted with room temperature PBS 
supplemented with 1 M trisodium citrate and 20% human serum albumin. 2 volumes of blood 
dilution were transferred in 50 ml tubes on a layer of 1 volume of Ficoll-Paque (Sigma-Aldrich). 
After centrifugation for 15 minutes at 800 g, the resulting layer of mononuclear cells was 
carefully removed, transferred to a new tube, further diluted using the same buffer and 
centrifuged for 6 minutes at 600 g. The resulting supernatant was removed, the pellet was 
resuspended in cold PBS supplemented with 0.5 M EDTA and 20% human serum albumin, and 
centrifuged again for 6 minutes at 600 g. Cells were then processed for CD34+ enrichment using 
labelling with magnetic beads. Briefly, cells were resuspended in the same PBS/EDTA/human 
serum albumin buffer, added with 50 μl/108 cells of FcR blocking reagent (Miltenyi Biotec) and 
50 μl/108 cells of CD34 magnetic beads (Miltenyi Biotec) and incubated for 30 minutes at 4 °C. 
After incubation, cells were washed using the same buffer and processed with AutoMACS Pro 
Separator to enrich for CD34+ peripheral blood mononuclear cells. 
 
7.4 May–Grünwald-Giemsa staining 
 
Cells were resuspended in culture media and concentrated by cytospin centrifugation at 
700 g for 5 minutes onto SuperFrostPlus slides (ThermoFisher Scientific) using a Shandon 
Cytospin 3 cytocentrifuge. Slides were fixed for 3 minutes in cold methanol and stained with 
May–Grünwald Giemsa (Sigma). Images were captured using a Leica DM5000b microscope in 





7.5 Flow cytometry 
 
Cells were dissociated into single cells using TrypLE for 3 minutes at 37 °C, washed with 
0.1% BSA-PBS and either fixed with 1% paraformaldehyde and kept at 4 °C for maximum 1 
week or immediately stained for flow cytometry. For the staining, after a wash with PBS, cells 
were blocked with 10% donkey serum (Bio-Rad) for 30 minutes at room temperature. Cells 
were then stained with the relevant conjugated antibodies (Table 7.1) diluted in PBS for 1 hour 
at room temperature, protected from light. Following two washes with PBS, cells were analysed 
using the Cyan ADP flow cytometer, or sorted on the BD Influx cell sorter. Data was analysed 
using the FlowJo VX software. 
Table 7.1 Antibodies used for flow cytometry 
Target  Dilution Supplier  Clone  
CD34 1:100 Biolegend 581 
CD43 1:25 BD Biosciences 1G10 
CDH5 1:50 Biolegend BV9 
CD44 1:50 Biolegend BJ18 
 
 
7.6 RNA extraction, cDNA synthesis and qPCR 
 
Total RNA was extracted using the GenElute Mammalian Total RNA Miniprep Kit 
(Sigma-Aldrich) and the On-Column DNase I Digestion set (Sigma-Aldrich) according to the 
manufacturer’s instructions. RNA was reverse-transcribed using 250 ng random primers 
(Promega), 0.5 mM dNTPs (Promega), 20 U RNAseOUT (Invitrogen), 0.01 M DTT 
(Invitrogen) and 25 U of SuperScript II (Invitrogen). For the qPCR reaction, the resulting 
cDNA was diluted 30-fold. Quantitative PCR mixtures were prepared using the KAPA SYBR 
FAST qPCR Master Mix Kit (Kapa Biosystems), 4.2 μl of cDNA and 200 nM of each of the 
forward and reverse primers (Table 7.2). Technical duplicates of the samples were run on 384 
well plates using the QuantStudio 12K Flex Real-Time PCR System machine and results 
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analysed using the delta cycle threshold (ΔCt) method. Expression values were normalized to 
the housekeeping gene RPLP0. 
Table 7.2 Primers used for qPCR 
Gene  Forward Primer (5’-3’)  Reverse Primer (5’-3’)  
CDH5 TGGCCAGCTGGTCCTGCAGAT TGCCCGTGCGACTTGGCATC 
CDK1 GGAAGGGGTTCCTAGTACTGC AAGCACATCCTGAAGACTGACT 
CDK2 CTCCAGGGCCTAGCTTTCTG CCGGCGAGTCACCTCATGG 
CDK4 TGAGGGGGCCTCTCTAGCTT CAAGGGAGACCCTCACGCC 
CDK6 ACAGAGCACCCGAAGTCTTG GGGAGTCCAATCACGTCCAA 
CDKN1A / p21 GGCAGACCAGCATGACAGAT GATGTAGAGCGGGCCTTTGA 
CDKN1B / p27 TAATTGGGGCTCCGGCTAAC GAAGAATCGTCGGTTGCAGGT 
CDKN1c / p57 GCTGCGGTGAGCCAATTTAG AACAAAACCGAACGCTGCTC 
CYCLIN B1 CGCCTGAGCCTATTTTGGTTG AGTGACTTCCCGACCCAGTA 
CYCLIN D1 GCTGTGCATCTACACCGACA AAATGAACTTCACATCTGTGGCA 
CYCLIN D2 GCCACCGACTTTAAGTTTGC CGGTACTGCTGCAGGCTATT 
CYCLIN D3 TGTGCTACAGATTATACCTTTGCC GCTTCGATCTGCTCCTGACA 
CYCLIN E1 GACGGGGAGCTCAAAACTGA TCGGGCTTTGTCCAGCAAAT 
GATA1 CTACACCAGGTGAACCGGC CTTTTCCAGATGCCTTGCGG 
GATA2 CTGTTCAGAAGGCCGGGAG AATTTGCACAACAGGTGCCG 
GFI1 ATCCACACTGGTGAGAAGCC GCTGCCCTCTGTAGTGTTGT 
LMO2 CAGAACATTGGGGACCGCTA GTCTTGCCCAAAAAGCCTGA 
KLF1 CCGAGGAAGAGGAGGCTTGAG GGAAGTCATCCTGTGTGTCCG 
MEIS1 GCGCAAAGGTACGACGATCT GGTACTGATGCGAGTGCAGA 
MYB GCTACTGCCTGGACGAACTG GTTGTTAACAGTGGGCTGGC 
PECAM1 CAGGCGCCGGGAGAAGTGAC CGTCCAGTCCGGCAGGCTCT 
RB1 CTGTGGATGGAGTATTGGGAGG TCTCATCTAGGTCAACTGCTGC 
RBL1 / p107 AGCAGAGGAGGATTCCTTGCAG GGGCACATAATCGCATTGGC 
RBL2 / p130 GCTACACGCTGGAGGGAAAT TCCTTCCACTGTCCCTTTGC 
RPLP0 GGCGTCCTCGTGGAAGTGAC GCCTTGCGCATCATGGTGTT 
RUNX1 CATCGCTTTCAAGGTGGTGG CATGGCTGCGGTAGCATTTC 
SPI1 CCCCACGACCGTCCAG GTAATGGTCGCTATGGCTCTCC 
TAL1 TACTGATGGTCCCCACACCA CCAGGCGGAGGATCTCATTC 




7.7 CFU assay 
 
The assay was performed using the MethoCult H4435 Enriched medium (STEMCELL 
Technologies), following the manufacturer’s instructions. Briefly, cells were added in a tube 
with the medium, mixed by vortex, plated on non-treated 35 mm culture dishes (Corning) and 
incubated for 14 days at 37 °C, 5% CO2 and 5% O2. Different types of colony were recognised 
based on morphology, counted and, when relevant, collected for RNA extraction. 
 
7.8 Cell cycle profile analysis 
 
Cell cycle profile analysis was performed using the Click-iT EdU Alexa Fluor 488 Flow 
Cytometry Assay Kit (ThermoFisher Scientific) according to the manufacturer’s instructions. 
Briefly, cultured cells were incubated at 37 °C with 10 μM EdU for 1 hour and harvested after 
dissociation with TrypLE. After 3 washes with 0.1% BSA-PBS, cells were fixed with 1% 
paraformaldehyde for 15 minutes at room temperature and washed three more times with 0.1% 
BSA-PBS. Cells were then permeabilised for 15 minutes with saponin-based 
permeabilisation/wash buffer and incubated with the Click-iT reaction cocktail for 30 minutes 
protected from light. Cells were washed once with saponin-based permeabilisation/wash buffer, 
stained for DNA content using DAPI (ThermoFisher Scientific) and analysed on the Cyan ADP 
flow cytometer and FlowJo VX software. 
 
7.9 Statistical analysis 
 
Statistical analyses were performed using the GraphPad Prism 7 software. The type of 
statistical analysis performed and the number of replicates used in each experiment are 
described in the figure legends. For the comparison of two or multiple groups, unpaired t-test 
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or one-way ANOVA test was performed, respectively. Significance in each analysis is 
represented as *P<0.5, **P<0.01, ***P<0.001, ****P<0.0001. 
 
7.10 Single cell RNA sequencing 
 
The bioinformatic analyses of the transcriptional data reported in this dissertation were 
performed with the help of Dr Emmanouil I. Athanasiadis from Dr Ana Cvejic’s group. 
All the methods were adopted as previously described (Butler et al., 2018). 
 
7.10.1 Single cell RNA processing 
 
Following dissociation, cells were resuspended at a concentration of 1,500 cells/μl in ice-
cold SP34 medium, complete with cytokines as for EHT culture. Libraries were constructed 
using Chromium Controller and Chromium Single Cell 3’ Library & Gel Bead Kit (10x 
Genomics) according to the manufacturer’s instructions for the recovery of 2,000 cells for each 
sample. Briefly, the cellular suspension was added to the master mix containing nuclease-free 
water, RT Reagent Mix, RT Primer, Additive A and RT Enzyme Mix. Master mix with cells was 
transferred to the wells in row 1 on the Chromium Single Cell A Chip (10x Genomics). Single 
Cell 3’ Gel Beads were transferred in row 2 and Partitioning Oil was transferred into row 3. The 
chip was loaded on Chromium Controller to generate single cell GEMs. GEM-RT was 
performed in a C1000 Touch Thermal cycler (Bio-Rad) at the following conditions: 53 °C for 
45 minutes, 85 °C for 5 minutes, held at 4 °C. Post GEM-RT clean-up was performed with 
DynaBeads MyOne Silane Beads (ThermoFisher Scientific). cDNA was amplified using C1000 
Touch Thermal cycler at the following conditions: 98 °C for 3 minutes, 12 cycles of (90 °C for 
15 seconds, 67 °C for 20 seconds and 72 °C for 1 minute), 72 °C for 1 minute, held at 4 °C. 
Amplified cDNA was cleaned with the SPRIselect Reagent Kit (Beckman Coulter) and quality 
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was assessed using 2100 Bioanalyser (Agilent). Libraries were constructed following the 
manufacturer’s protocol and sequenced in pair-end mode on Hi-Seq4000 platform. 
 
7.10.2 Alignment and quantification of sequencing data 
 
Cell Ranger v2.10 was used in order to de-multiplex raw base call (BCL) files generated 
by Illumina sequencers into FASTQ files, perform the alignment, barcode counting and UMI 
counting. Ensembl BioMart version 91 was used to generate the reference genome. 
 
7.10.3 Quality control of sequencing data 
 
Data was filtered based on the Median Absolute Deviation (MAD) of the distribution of 
the number of detected genes. In addition, the percentage of mitochondrial content was set to 
less than 20%. Following quality control, 3,877 single cells from EHT D3, 2,152 from EHT D5, 
1,742 from PD0332991 (CDK4/6i), 2,140 from Roscovitine (CDK2/1i) and 1,741 from RO3306 
(CDK1i) were used in downstream analyses. 
 
7.10.4 Seurat Alignment Strategy 
 
In order to perform a direct comparison of clusters that belonged to the same cell type 
across different conditions, we adopted the Seurat Alignment workflow (Butler et al., 2018). We 
calculated Highly Variable Genes (HVGs) for each of the different conditions. HVGs were 
detected based on their average expression against their dispersion, by means of the 
“FindVariableGenes” Seurat command with the following parameters: mean.function equal to 
ExpMean, dispersion.function equal to LogVMR, x.low.cutoff equal to 0.0125, x.high.cutoff 
equal to 3, and y.cutoff equal to 0.5. For the analysis of EHT D3 and EHT D5 we selected 1,289 
common HVGs that were expressed in both datasets. For the analysis of EHT D5, CDK4/6i, 
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CDK2/1i and CDK1i we selected 2,306 HVGs that were expressed in at least 2 out of 4 samples. 
Canonical Correlation Analysis (CCA) was then performed in order to identify shared 
correlation structures across the different conditions using the “RunMultiCCA” command. 
Twenty significant CCA components were selected by means of the shared correlation strength, 
using the “MetageneBicorPlot” command in both cases. Aligned CCA space was then generated 
with the “AlignSubspace” Seurat command. Significant CCA aligned components were then 
used to create the 3D tSNE space using the “RunTSNE” Seurat command. 
 
7.10.5 Downstream analysis of sequencing data 
 
For the clustering in the 3D tSNE space we used the “FindClusters” command in Seurat 
that performs the Shared Nearest Neighbor (SNN) modularity optimization based clustering 
algorithm in Correlation Component Analysis (CCA) aligned space. In total, thirteen clusters 
were identified using SNN modularity optimisation based clustering algorithm on the 35 
significant CCA aligned components at 0.6 resolution. Positive marker genes that were 
expressed in at least half of the cells within the thirteen identified clusters were calculated with 
“FindAllMarkers” Seurat command, using Wilcoxon rank sum test with the threshold set to 
0.25. We over-clustered the cells and then calculated for each cluster the average expression 
level of the top 20 marker genes. After calculating the correlation across the clusters we merged 
those with a correlation higher than 0.9. By merging the most highly correlated, we ended up 
with 4 clusters, and by calculating marker genes we were able to assign cell identity to the 
resulting clusters. 
 
7.10.6 Pseudotime ordering 
 
The set of common HVGs was used to order cells along a pseudotime trajectory using 
the Monocle2 R package v1.99.0. The ‘tobit’ expression family and ‘DDRTree’ reduction 
method were used with the default parameters. Finally, we identified genes that change as a 
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function of pseudotime across each of the three branches by setting the ‘fullModelFormulaStr’ 
parameter equal to '~sm.ns(Pseudotime)'. For the subclustering, we retrieved only the 
endothelial cluster (cluster 1) and performed separate clustering on the Monocle space using 
the strategy previously described for the tSNE space, ending up with 4 subclusters. 
 
7.10.7 Cell cycle analysis 
 
In order to infer cell cycle states in our single cell data we adopted the Satija’s single cell scoring 
strategy (Butler et al., 2018). In more details, we assigned to each cell a score based on its 
expression of G2/M and S phase markers. These marker sets should be anticorrelated in their 
expression levels, and cells not expressing either are likely not cycling or in G1 phase. We 
assigned scores in the ‘CellCycleScoring’ function, which stores S and G2/M scores in 
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